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1.   INTRODUCTION  
 
1.1.TRADITIONAL MEDICINE SYSTEM 
Traditional system of medicine is one of the centuries old practice and long-
serving companion to humankind in the fight against disease and in leading a healthy life. 
Indigenous people have been using the unique approach of their traditional system of 
medicine for centuries and among the most renowned are the Chinese, Indian, African 
systems of medicine. Traditional medicine refers to any ancient and culturally based 
healthcare practice differing from scientific medicine and is largely transmitted orally by 
communities of different cultures.[1] The World Health Organization (WHO) observes that 
it is difficult to assign one definition to the broad range of characteristics and elements of 
traditional medicine, but that a working definition is essential. It thus concludes that the 
traditional medicines ‘‘[include] diverse health practices, approaches,  knowledge and 
beliefs incorporating plant, animal and mineral based medicines, spiritual therapies, 
manual techniques and exercises applied singularly or in combination to maintain well-
being, as well as to treat, diagnose or prevent illness.[2] 
 
        Several developed countries have a major proportion of the population that uses 
traditional practice of health, especially medicinal plants, and have taken steps to preserve 
its popularity for historical and cultural reasons. Moreover, it has been reported that more 
than70% of the developing world’s population still depends on the complementary/ 
alternative systems of medicine, otherwise known as traditional medicine, for example, up 
to 80% of the population in Africa, 71% in Chile, and 40% in Colombia, and others.[3] 
  
The modern health care service has posed immense threat to indigenous health 
practices because of their potential and speedy therapeutic effect. This has led to the 
disappearance and displacement of traditional systems of medicine. Also, traditional 
systems are undervalued by the people. However, the rise in population, inadequate supply 
of drugs, prohibitive cost of treatments, side effects of several allopathic drugs and 
development of resistance to currently used drugs for infectious diseases have led to 
increased emphasis on the use of plant materials as a source of medicine for a wide variety 
of human ailments.[1] 
 
 1.1.2. History of Traditional and Herbal Medicine 
The use of plants as medicine goes back to the period of early humans. Fossil 
records  human use of plants as medicines at least to the Middle Paleolithic age. Evidences 
of this early association have been found in the grave of a Neanderthal man buried 60,000 
years ago. The earliest known medical document is a 4000-year-old Sumerian clay tablet 
that recorded plant remedies for various illnesses. By the time of the ancient Egyptian 
civilization, a great wealth of information already existed on medicinal plants. This 
information, along with the hundreds of other remedies, has been preserved in the Ebers 
papyrus for nearly 3500 years. [4]  
 
The development of systematic pharmacopoeias dates back to 3000 BC, when the 
Chinese were already using more than 350 herbal remedies. China has demonstrated the 
best use of traditional medicine in providing health care. Ayurveda, a system of herbal 
medicines widely practiced in India, Sri Lanka, and Southeast Asia has more than 8000 
plant remedies and uses nearly 35,000 to 70,000 plant species. Among the ancient 
civilizations, India have been known to be the richest repository of medicinal plants. 
About 8000 herbal remedies have been codified in Ayurveda. The Rigveda (5000 BC) has 
recorded 67 medicinal plants, the Yajurveda 81 species, the Atharvaveda (4500-2500 BC) 
290 species, and the Charak Samhita (700 BC) and Sushrut Samhita (200 BC) have 
described properties and uses of 1100 and 1270 species, respectively, to compound the 
drugs and use.[5] 
  
It is a well known fact that Traditional Systems of medicines always played 
important role in meeting the global health care needs. They are continuing to do so at 
present and shall play major role in future also. The system of medicines which are 
considered to be Indian in origin or the systems of medicine, which have come to India 
from outside and got assimilated in to Indian culture are known as Indian Systems of 
Medicine. India has the unique distinction of having six recognized systems of medicine in 
this category. They are: Ayurveda, Siddha, Unani and Yoga, Naturopathy and 
Homoeopathy.[6]  
 
 1.1.3. Traditional System of Medicines[7] 
 
 Ayurveda 
 Unani 
 Homeopathy 
 Siddha 
1.1.4. Ayurveda 
Ayurvedic medicine is a system of traditional medicine native to the Indian 
subcontinent and practiced in other parts of the world as a form of traditional medicine. In 
Sanskrit, the word ayurveda consist of the word sayus, means "longevity", and veda, 
means "related to knowledge" or "science". Evolving throughout its history, ayurveda 
remains an influential system of medicine in South Asia. The earliest literature on Indian 
medical practice appeared during the vedic period in India. The Susruta Samhta and the 
Charaka Samhta - where influential works on traditional medicine during this era. 
Ayurveda is considered to be a form of Complementary and Alternative Medicine (CAM) 
in the western world, where several of its methods, such as the use of herbs, massage, and 
yoga, are applied on their own as a form of CAM treatment.  
Ayurveda is the ancient (before 2500 B.C.)  Indian system of health care involving 
a holistic view of man, his health, and illness. Ayurvedic treatment of a disease consists of 
salubrious use of drugs, diets, and certain practices. Medicinal preparation is invariably 
complex mixtures, based mostly on plant products. Around 1, 250 plants are used in 
various ayurvedic preparations. 
Many Indian medicinal plants have come under scientific scrutiny since the middle 
of the nineteenth century, although in a sporadic fashion. 
The first significant contribution from ayurvedic material medica came with the 
isolation of the hypertensive alkaloids from the sarpagandha plant (Rauwolfia serpentina), 
valued in ayurveda for the treatment of hypertension, insomnia and insanity. This was the 
first important ancient-modern concordance in ayurvedic plants. 
 
 According to ayurveda, all objects in the universe including human body are 
composed of five basic elements (Panchamahabhutas) namely, earth, water, fire, air and 
vacum (ether).   
There is a balanced condensation of these elements in different proportions to suit 
the needs and requirements of different structures and functions of the body matrix and its 
parts. The growth and development of the body matrix depends on its nutrition, i.e. on 
food. The food, in turn, is composed of the above five elements, which replenish or 
nourish the like elements of the body after the action of bio-fire (agni).  
The tissues of the body are the structural whereas humours are physiological 
entities, derived from different combinations and permutations of Panchamahabhutas. 
Treatment of the disease consists in avoiding causative factors responsible for 
disequilibrium of the body matrix or of any of its constituent parts through the use of 
Panchkarma procedures, medicines, suitable diet, activity and regimen for restoring the 
balance and strengthening the body mechanisms to prevent or minimize future occurrence 
of the disease. 
Use of these three measures is done in two ways. In one approach of treatment the 
three measures antagonize the disease by counteracting the etiological factors and various 
manifestations of the disease. 
 In the second approach the same three measures of medicine, diet and activity are 
targeted to exert effects similar to the etiological factors and manifestations of the disease 
process. These two types of therapeutic approaches are respectively known as Vipreeta 
and Vipreetarthkari treatments. 
1.1.5. Siddha 
Siddha system is one of the oldest systems of medicine in India. The term siddha 
means achievements and siddhars were saintly persons who achieved results in medicine. 
Eighteen Siddhars were said to have contributed towards the development of this medical 
system. Siddha literature is in tamil and it is practiced largely in tamil speaking part of 
India and abroad. The siddha system is largely therapeutic in nature. 
 This principles and doctrines of this system, both fundamental and applied, have a 
close similarity to ayurveda, with specialization in nitro-chemistry. According to this 
system the human body is the replica of the universe and so are the food and drugs 
irrespective of their origin. 
 Like ayurveda, this system believes that all objects in the universe including 
human body are composed of five basic elements namely, earth, water, fire, air and sky. 
The food, which the human body takes and the drugs it uses are all, made of these five 
elements. The proportion of the elements present in the drugs vary and their 
preponderance or otherwise is responsible for certain actions and therapeutic results. As in 
ayurveda, this system also considers the human body as a conglomeration of three 
humours, seven basic tissues and the waste products of the body such as feces, urine and 
sweat. The food is considered to be basic building material of human body which gets 
processed into humours, body tissues and waste products. The equilibrium of humours is 
considered as health and its disturbance or imbalance leads to disease or sickness.  
This system also deals with the concept of salvation in life. The exponents of this 
system consider achievement of this state is possible by medicines and meditation. 
The siddha system is capable of treating all types of disease other than emergency 
cases. In general, this system is effective in treating all types of skin problems particularly 
psoriasis, STD, urinary tract infections, diseases of liver and gastro intestinal tract, general 
debility, postpartum anemia, diarrhea and general fevers. 
1.1.6. Unani 
Unani system of medicines originated in Greece and is based on the teachings of 
Hippocrates and Gallen and it developed in to an elaborate medical system by Arabs, like 
Rhazes, Avicenna, Al-Zahravi, Ibne-Nafis and others. Unani medicines got enriched by 
imbibing what was best in the contemporary systems of traditional medicines in Egypt, 
Syria, Iraq, Persia, India, China and other Middle East countries. In India, unani system of 
medicine was introduced by Arabs and soon it took firm roots. The Delhi Sultans (rulers) 
provided patronage to the scholars of unani system and even enrolled some as state 
employees and court physicians. During 13th and 17th century A.D. Unani medicine had 
its hey-day in India. During the British rule, unani system suffered a setback due to 
withdrawal of State Patronage, but continued to be practiced as the masses reposed faith in 
the system. It was mainly Sharif family in Delhi, the Azizi family in Lucknow and the 
Nizam of Hyderabad due to whose efforts unani medicine survived during the British 
period. In India, the concept of research in unani system of medicine was originally 
perceived by Masih-ul-Mulk Hakim Ajmal Khan in the 1920s. A versatile genius of his 
time, Hakim Ajmal Khan spotted Dr. Salim uzzaman Siddiqui- a chemist- for undertaking 
chemical studies on some important medicinal plants used in unani medicine.Dr. Siddiqui 
undertook the task visualized by Masih-ul-Mulk and his discovery of medicinal properties 
of a plant, commonly known as Asrol (Pagalbooti), led to sustained research that 
established the unique efficacy of this plant known all over the world as Rauwolfia 
serpentina, in neurovascular and nervous disorders, such as hypertension, insanity, 
schizophrenia, hysteria, insomnia and psychosomatic conditions, etc., 
1.1.7. Homeopathy 
Homeopathy, founded by a German physician Samuel Hahnemann in 1790, is 
based on the idea that ‘like cures like’ that is substances that cause certain symptoms in a 
healthy person can also cure those same symptom in someone who is sick. This so called 
low of similar gives homeopathy its name ‘homeo’ for similar ‘pathy’ designating disease. 
In this experiment Hahnemann developed a method of ‘potentizing’ homeopathic 
remedies by diluting them in a water-alcohol solution and then vigorously shaking the 
mixtures.  
The result convinced him that a high degree of dilution not only minimizes the side 
effects of the remedies but also simultaneously enhances their medical efficacy. Most 
Homeopathic remedies have undergone ‘proving’ or medical observation in which healthy 
individuals are given doses of undiluted homeopathic substances. 
Mental, emotional, and other details of the patients are most important. This leads 
the physician to a better understanding of which remedy will best suits a particular set of 
symptoms. Over the past 200 years, providing for almost 2,000 substances have been 
conducted. 
 
1.1.8. Current Status of Herbal Medicine 
    Currently more than 80% of the world population depends on traditional and plant 
derived medicine because, plants are important sources of medicines and presently about 
25% of pharmaceutical prescriptions in the United States contain at least one plant-derived 
ingredient. In the last century, roughly 121 pharmaceutical products were formulated 
based on the traditional knowledge obtained from various sources.[8] 
1.1.9. Future importance of Herbal Medicine  
It is estimated that there are about 350,000 species of existing plants (including 
seed plants, bryophytes, and ferns), among which 287,655 species have been identified as 
of 2004. Relatively small percentages (1 to 10%) of these are used as foods by both 
humans and other animal species. It is possible that even more are used for medicinal 
purpose .[8] 
The strategy has four main objectives, in line with those of WHO’s medicines 
strategy: 
Objectives  
• To integrate relevant aspects of traditional medicine within national         
   health care systems by framing national traditional medicine Policies  
   and implementing  programmes 
• To Promote the safety, efficacy and quality of Traditional Medicine      
   Practices by providing guidance on regulatory and quality assurance  
  standards  
• To increase access to, and affordability of, traditional medicine 
• To promote rational use of traditional medicine implementation 
1.1.10. Policy 
A national policy is urgently needed in those countries where traditional medicine 
is popularly used in primary health care, and governments are becoming increasingly 
aware of it. For instance, in the Western Pacific Region, only four countries had a national 
policy on traditional medicine in 1994 the number had risen to 14 by 2001.  
In general, such policy should include a definition of the government’s role in 
developing traditional medicine in the health-care delivery system, and contain a mission 
as well as goals and objectives. Integration of traditional medicine into the national health 
system will enable the two systems to work effectively together, to the benefit of the 
government, patients and consumers.  
1.1.11. Safety, efficacy and quality 
 Governments need to undertake a series of activities to ensure the safety 
and efficacy of traditional medicine, including establishment of a national 
expert committee, formulation of national regulations for herbal medicines, 
licensing of the practice of traditional medicine, and provision of support 
for research 
 Member States are becoming increasingly aware of the importance of the 
safety and efficacy of traditional medicine. Countries with regulations on 
herbal medicines have increased from 50 in 1994 to 70 in 2001. National 
research institutes for traditional medicine have also been established and 
research funding has increased. For example, in the African Region, 21 out 
of 46 countries have institutes carrying out research in traditional medicine 
Access 
Low-income countries need inexpensive and effective treatment for 
common diseases. The fact that traditional medicine practitioners live and 
work at community level makes such treatment available and affordable to 
most of the population. The role of traditional practitioners should be 
recognized and cooperation between them and community health-workers 
should be strengthened                                          
Rational use 
Traditional medicine is provided not only by traditional practitioners, but 
also by medical doctors. In Canada, 57% of herbal therapies, 31% of 
chiropractic and 24% of acupuncture treatment are provided by general 
practitioners. In the Netherlands, 50% of general practitioners prescribe 
herbal medicines and provide manual therapies and acupuncture.  
The communication between doctors and traditional practitioners 
should be strengthened and appropriate training programmes established. 
Further, as traditional medicine is mostly used as self-care, health 
authorities should develop education and training programmes for 
consumers on its proper use.[9] 
1.1.12. NEEM 
 The Neem tree (Azadirachta indica) is a tropical evergreen tree native to 
India and is also found in other southeast countries. In India, neem is known as “ 
the village pharmacy” because of its healing versality and it has been used in 
Ayurvedic medicine for more than 4,000 years due to its medicinal properties. 
Neem is also called “arista” in Sanskrit – a word that means Perfect, complete and 
imperishable.  
          The seeds, bark and leaves contain compounds with proven antiseptic, 
antiviral, antipyretic, anti- inflammatory, anti-ulcer and antifungal uses. The 
Sanskrit name “nimba” comes from the term “nimbitisyasthyamdadati”   which 
means ‘to give good health’. 
 Important uses of various parts of neem tree  
 Neem oil is extracted from the seeds of the neem tree and has insecticidal 
and medicinal properties due to which has been used for thousands of 
years in pest control, cosmetics, medicines, etc., 
 Neem seed cake (residue of need seeds after oil extraction) when used 
for soil amendment or added to soil, not only enriches the soil with 
organic matter but also lowers nitrogen losses by inhibiting nitrification. It 
also works as a nematicide 
 Neem leaves are used to treat chickenpox and warts by directly applying 
to the skin in a paste form or by bathing in water with neem leaves. In 
order to increase immunity of the body, neem leaves are also taken 
internally in the form of neem capsules or made into a tea. The tea is 
traditionally taken into internally to reduce fever caused by malaria 
 In Ayurveda, neem leaves are used in curing neuromuscular pains. Neem 
leaves are also used in storage of grains 
 Twigs of neem are also used in India and Africa as tooth brushes. 
Nowadays tooth pastes with neem extracts are also available commercially 
 Neem (leaf and seed) extracts have been found to be spermicidal and thus 
research is being conducted to use neem extracts for making 
contraceptives  
 Neem produces pain relieving, anti-inflammatory and fever reducing  
compounds that can aid in the healing of cuts, burns, ear aches, sprains 
and  headaches, as well as fevers 
 Neem bark and roots also have medicinal properties. Bark and roots in 
powdered form are also used to control fleas and ticks on pets 
 Neem has anti-bacterial properties that helps in fighting against skin 
infections such as acne, psoriasis, scabies, eczema, etc., 
 Neem extracts also help sin treating diabetes, aids, cancer, heart disease, 
herpes, allergies, ulcers, allergies, ulcers, hepatitis and several other 
disease 
 Neem leaves and neem extracts are used to manufacture health and 
beauty care products[10] 
1.1.13. NEEM IN TRADITIONAL SYSTEM OF MEDICINE  
           The therapeutic efficacy of neem must have been known to man since antiquity as a 
result of constant experimentation with nature. Ancient man observed the unique features 
of this tree a bitter taste, non- poisonous to man, but deleterious to lower forms of life.  
Ayurveda 
          The word neem is derived  from Sanskrit Nimba, which means “to bestow health”, 
the various Sanskrit synonyms of neem signify the pharmacological and therapeutic effect 
of the tree. Ayurveda the word neem is derived from Sanskrit Nimba, which means “to 
bestow health”, the various Sanskrit synonyms of neem signify the pharmacological and 
therapeutic effects of the tree.It has been nicknamed Neta- a leader of medicinal plants, 
Pichumarda- anti leprotic, Ravisambba- sunray-like effects in providing health,  
Arishta - resistant to insects, beetal-cooling (cools the human system by giving relief  in 
disease  caused  by hotness, such as skin disease and fever) and Krimighana - 
Anthelmintic. 
Ayurvedic  products 
Some of the important poly herbal neem preparations of Ayurvedic pharmacopoeia 
and their main uses are : 
 Aparjith  Dhttp - fumigant for purification for air (air sterilizer) 
 Erhamanisthadith Kwath - skin disease 
 Dhatturtailam -  oil for skin disease and muscular pain 
 Jatyaditailam - oil for ulcer 
 Jeevantiadi kashyam - for small pox 
 Laghumanjishtadi Kwath - decoction for skin disease 
 Kandavadu  Lepah - poultice for itching 
 Mahatikatamghritam  - butter fat for skin diseases 
 Nimbadikashyam - for skin disease [11] 
Unani  
           In the Greco - Persian system of medicine (Unani tibb), which was patronized by 
muslim rulers in the medieval era in the Indian subcontinent, the leaves and fruit were in 
the pharmacopeia. As per this system, neem is cold 1°,dry 2°, a resolvent and blood 
purifier. Neem leaves, called “burgh-i-neem”, are said to expel foul wind from the body 
and heal ulcers in the urinary passage  it is an emenagogue and good for skin disease. 
Unani Products 
            Neem leaves, bark, seed and oil are incorporated in some of the unani preparations 
as follow: 
 ArqGaz - a distillate from all five parts of the neem tree, used for fevers 
due to inflammation of the spleen 
 Arqharabhara -  a distillate from the seed coat, tonic for the lungs 
 Arqmurakkabmussaffakhun - a distillate from the seed coat, a tonic for the  
lungs 
 Habnarkachur - anti-inflammatory for children 
 Habsiyahchatham - for application inside the eyelid in conjunctivitis[12] 
 
Homeopathy 
           Homeopathic remedy Azadirachta indica to treat health problems. Neem used in 
homeopathy system of medicine due to its immense health benefiting qualities. It is boon 
for skin when used both internally and externally. It detoxifies blood and cures acne, 
pimples, boils and similar condition neem is bitter in taste. But this bitterness is 
responsible for its therapeutic efficacy of this tree. 
Homeopathic remedy  
 Ozena: A chronic disease of the nose accompanied by a field discharge. It is 
characterized by structural changes in nose 
 Pemphigus: It is a skin disease in which there  are watery blisters 
 Scabies: It is disease which is spread from one person to another very easily and 
characterized by itching and small raised red spots. It is caused by itch mite 
 Leprosy: It is a disease that causes symptoms on skin, mucous membrane, and 
nerves. It causes loss  of color of skin and in severe cases causes disfigurement and 
deformities 
 Helminthiasis: It  is a disease which is caused by worms 
 Gonorrhea: It is sexually transmitted disease which causes discharge from urethra 
or vagina 
 Glossitis: Inflammation of the tongue 
 Ophthalmia: Inflammation of the eye 
 Asthma: It is a respiratory condition which is marked by attacks of spasm in lungs, 
causing difficulty in breathing. It is basically allergic reaction 
 Catarrh: It is basically inflammation of the mucous membrane which causes 
excessive discharge of mucus in the nose or throat 
 Constipation: It is a condition which characterized by hardened stools 
 Uterine weakness: it is associated with pregnancy, childbirth, lifting, coughing, 
damage to or weakness of the muscles[13] 
Siddha 
 Siddha medicine is one of the important traditional medicinal systems, which is 
popular among Tamils. Siddha mediccines have effective treatment for many skin 
problems such as psoriasis, eczema, leucoderma, skin rashes, pimples, itching, acne, 
wrinkles, black spots, white spots and breast nipple discoloration. This safe and cost 
effective natural treatment modality is also good for skin allergy, skin whitening and other 
skin related problems. 
Siddha Medicinal Uses 
 The leaf juice in the dose of 10-20 ml is administered along with equal amount of 
honey three times a day for jaundice, intestinal worms etc., 
 Neem oil along with equal amount of castor oil is given early morning in empty 
stomach to remove the intestinal worms 
 The leaves of this plant along with turmeric is ground together and applied over the 
areas of insect bite, sori, (skin disease), sirangu (scabies), fungal infection, 
karappan (eczema) 
 The decoction prepared from leaves and bark is used to clean the ulcers and skin 
disease 
 The leaf paste is applied over the burns 
 The decoction prepared from the flowers is helpful in treating Gunmam or 
abdominal disorders 
 The fruit is dried and the seeds are removed, this is then powered and is given in 
the dose of 1-10 grams two times a day for periodic fever 
 The oil prepared from neem is an anti-septic and applied externally for ulcers, 
eczema, and sirangu 
 Neem oil is used over herpes infection keelvayu or arthritis and kandamalai 
(cervical lymphadenitis) 
 The neem oil , 5-6 drops is given along with milk in diabetes Tender leaves of 
neem is an excellent medicine for diabetic patients [14].  
 
 
 
1.2. NOVEL DRUG DELIVERY SYSTEM [15] 
The   aim of   Novel  Drug Delivery   System  is to provide a therapeutic amount  
of  drug  to  the appropriate  site  in  the  body  to   accomplish  promptly and then 
maintain   the   desired  drug  concentration. The drug- delivery system should deliver 
drug  at  a  rate  control  by  the necessarily of the body over a specified  term of treatment.  
These idealized objective switches to the two aspects most important to drug delivery are 
as follows: 
I. Spatial Drug Delivery:       
Targeting a drug to a  particular organ or tissue. 
II. Temporal Drug Delivery:  
             The drug delivery rate to the target tissue is controlled.  
The prime areas of research and development for NDDS are:  
 Liposomes   
 Niosomes 
 Nanoparticles  
 Transdermal drug delivery    
 Implants  
 Oral system  
 Micro encapsulation / Microcapsules  
 Polymer in drug delivery   
Novel drug delivery system can be divided into classes: 
1. Sustained diffusion drug delivery system 
2. Controlled diffusion drug delivery system 
Sustained diffusion drug delivery system  
 It is a pharmaceutical dosage from formulated to retard the diffusion of a    
therapeutic effect such that its look in the systemic circulation is delayed and or prolonged 
and the plasma profile is  sustained in duration. The onset of its pharmaceutical action is 
often slow, and the duration of its therapeutic effect is sustained. (Eg: coated granules)   
 
 
 
 
 
Controlled diffusion drug delivery system  
This   system has a   meaning that goes beyond the   scope of sustained drug action. 
It Many fests a predictability and reproducibility in the drug diffusion kinetics. The 
diffusion of drug substances from a   controlled   diffusion drug delivery system gains at a 
rate profile that is not only predictable kinetically but also reproduced from one unit to 
another.  
They are classified as follows: 
I. Rate - preprogrammed drug delivery system 
            II. Activation - Modulated drug delivery system 
            III. Feed - Back Regulated drug delivery system 
            IV. Site - Targeting drug delivery system 
1.2.1. Merits of drug delivery system 
1.  Better treatment of many chronic illnesses. Eg. Cancer, Asthma,   Arthritis 
2.  Increased Bio- availability 
3. Reduction in the occurrence and badness of untoward systemic side effects 
related to high blood plasma drug concentration 
4.  Sustenance of the total amount of drug administered over the period dose 
periods  
5. Reduction in the total amount drug administered over  the  period of drug 
treatment  which  reduce  occurrence of  systemic and local side effects 
 6. Prevention from   first   pass    metabolism    and   gastrointestinal      tract    
degradation 
7. Better patient compliance effect   from   the   reduction in   the number and 
frequency of   doses   needed   to maintain the   want therapeutic responses 
8. Targeting the drug molecule towards the affected tissue or organ make smaller 
the  toxicity to the normal tissues       
9. Versatile and pH dependent   system diffusion the drug whenever the body 
demands 
10. Biocompatibility 
 
 
 
 
 1.2.2. Limitations  
Factors that limit its usage 
1. Physiological  factors  such  as   gastro  intestinal  enzyme, activates pH /gastric and   
intestinal  transit   rates,   food  and  disease   which   often  influence  drug   
bioavailability  from conventional dosage   forms   may   interfere  with    the   accuracy  
of control  diffusion  and  absorption  of  drug  from the system. 
2. The   products which remain intact may become accommodates at some sites results 
slow diffusion of drug from the dosage form may produce a high   localized concentration 
of   drug which produces local irritation. 
3. Drugs with half - life of 1hr or less are difficult to be formulated   as   sustained                
diffusion    formulation.   The   high   rate   of elimination  of  such  drugs  from  the  body  
requires  an highly large maintenance    dose which  provides  8-12 hrs  of  continuous 
diffusion. 
4. Since these products contain a large amount of drug. There is a chance  of   unsafe      
over  dosage, if the product  is improperly  made and  the  total  drug  contained  there  is 
diffusion  at one time or over too short  time  of  interval. 
5.  It  is  difficult  to  cease the  therapy once after  administration  may  be  for reasons  of  
toxicity  or any other. 
6. It may be not suitable to encompass potent drugs in such system. 
 
1.3. TOPICAL DRUG DELIVERY SYSTEM [16] 
Topical drug delivery can be defined as application of drug via skin to directly 
treat or cure the skin disorders. These systems are generally used for local skin infection 
like fungal infection or in place where other routes of the drug administration fails. 
Topical dosage forms are generally confined to a small area anywhere in the body through 
ophthalmic, rectal, vaginal and skin as route. Skin is one of the most easily accessible 
organ of human body.  
Skin of an average adult body covers a surface of about 2m2 and receives around 
one-third of the blood circulating through the body. Over the past three decades, controlled 
drug delivery has become increasingly important in the pharmaceutical industry. The 
surface of human skin is known to contain, on an average, 10 -70 hair follicles and 200 to 
250 sweat ducts on every cm2 of the skin area. Skin is a very difficult barrier to the ingress 
materials allowing only small quantities of drug molecules to penetrate over a period of 
time.  
 Transport of hydrophilic or charged molecules is especially difficult attributable to 
the lipid-rich nature of the Stratum corneum and its low water content this layer is 
composed of about 40% lipids, 40% protein, and only 20% water. Transport of lipophilic 
drug molecules is facilitated by their dissolution into intercellular lipids around the cells of 
the Stratum corneum. Absorption of hydrophilic molecules into skin can occur  through 
‘pores’ or openings of the hair follicles and sebaceous glands, but the relative surface area 
of these openings is barely 1% of the total skin surface. This small surface area limits the 
amount of drug absorption.  
Precutaneous absorption of drug molecules is a key factor of particular importance 
in the case of topical drug delivery systems because the drug has to be absorbed to an 
adequate extent and rate to achieve and maintain uniform, systemic, therapeutic levels 
throughout the duration of use. 
 In general, once drug molecules cross the stratum corneal barrier, passage into 
deeper dermal layers and systemic uptake occurs relatively quickly and easily. Drugs with 
the lipophillic character, are better suited for topical delivery.  
These systems ensure that the drug get into the body and reach the area where it is 
needed.  These preparations are applied onto the skin surface for providing local or 
systemic effects. Topical route favours safe and effective delivery of drug molecules with 
lower doses as compared to the conventional system. Drugs via skin reaches the desired 
area in optimum concentration, dropping the chances of side effects leading to increased 
bioavailability and increased patient compliance. Dermatological conditions i.e. skin 
disease affects the population and has been observed as one of the top 15 medical 
conditions for which prevalence and healthcare spending have increased in the last decade.  
 
Advancements in the life sciences united with a growing market for dermatological 
have facilitated the emergence of better topical formulations and drug delivery systems. 
The present and emerging approaches of optimizing the topical dermatological agents 
delivery (i.e small and large molecules) includes the use of chemical enhancers, 
liposomes, bio-polymers (sodium hyaluronate),  particulate carriers (microspheres and 
lipid nanoparticles), occlusion (via dressings and patches) topical peels, topical sprays and 
foams, temperature (heat), iontophoresis and ultrasound.  
 
 These delivery approaches are a significant advancement over conventional 
systems (i.e creams, lotions, ointments and pastes) and are likely to enhance efficacy and 
tolerability, improve patient compliance (which include dermatology life quality), and also 
fulfill other required needs of the topical dermatological market.  
However, the limited dermal and transdermal delivery of many small and large 
molecules is a significant challenge because of the unyielding barrier properties of the 
skin. This paper reviews the application of a novel topical delivery system, employing 
sophisticated carriers built from nanoscale components, to the delivery of several 
therapeutic agents and discusses progress toward its clinical application. 
1.3.1. Advantages of topical drug delivery systems [17] 
 Avoidance of the first pass metabolism  
 Convenient and easy to apply 
 Avoidance of risks and inconveniences of the intravenous therapy and of 
diverse conditions of absorption like pH  changes, presence of enzymes, gastric 
emptying time  
 Easily terminate the medications, when needed  
 Deliver drug more selectively to a specific site   
 Avoidance of the gastro-intestinal incompatibility 
 Providing utilization of drugs with short biological half life, narrow therapeutic 
window  
 Improved patient compliance   
 Provide suitability for self-medication 
 Achievement of effectiveness with lower total daily dose of drug by continuous 
drug input 
 Avoids fluctuation in drug levels, inter- and intra patient variations  
 A quite large area of application in comparison with buccal or nasal cavity  
 Ability to deliver drugs more selectively to a specific site 
 
 
 
 
1.3.2 Disadvantages of topical drug delivery systems 
 Skin irritation or dermatitis may occur due to the drug or excipients 
 Poor permeability of some drugs through skin   
 Drugs with larger particle size can’t be easily absorbed  through the skin  
 Risk of allergenic reactions 
 Can be used only for the drugs which need very small plasma concentration for 
action 
 
1.4. SKIN [18] 
                  The skin completely covers the body and is continues with the membranes 
lining the body orifice. 
 It protects the underlying structures from injury and from invasion by microbes 
 It contains sensory (somatic)nerve endings of pain, temperature and touch 
 It is involved in the regulation of body temperature 
1.4.1. Structure of the skin 
                
Fig No.1: Structure of skin 
The skin is the largest organ of human body, accounting for about 15% of the 
whole adult body weight. Skin is one of the most readily accessible parts of the human 
body for topical administration. Penetration of molecules in the skin mainly occurs 
through three routes through intact stratum corneum, through the sebaceous follicle and 
through sweat ducts.  
 
Topical drug delivery approach is used for localized action on the body through 
skin, ophthalmic, rectal and vaginal as topical routes.  
Skin performs various important functions: 
 Protection against the physical, biological and chemical assailants 
 Prevention of excess loss of water from the body  
 Vital role in the thermoregulation 
 Enzyme in epidermis can denature the drugs  
The skin consists of three layers that are the epidermis, the dermis and the 
subcutaneous tissue. An average human skin surface contain, on an average 40-70 hair 
follicles and 200-300 sweat ducts on every cm² of the skin. The pH of the skin vary from 
4- 5.6 the skin of an average adult body covers a surface area of about 2m² and receives 
about one third part of the blood circulating through the body. 
1.4.2. Epidermis 
  It is a stratified squamous epithelium layer which is composed primarily of two 
types of cells dendritic and keratimocytes cells. The epidermis layer harbour a number of 
other cells such as melanocytes, Merkel cells and Langerhans cells. But the keratinocytes 
cells type comprises the majority of the cells by far.  
 Stratum germinativum (basal layer or rowing layer): It contains column-shaped 
keratinocytes that attach to the zone of  basement membrane with their long-axis 
perpendicular to the dermis  
 Stratum spinosum (prickly cell layer or squamous cell layer): Its thickness vary 
from 5-10 cells. Intercellular spaces between spinous cells are bridged by abundant 
desmosomes (adhering spot) to promote coupling between cells of the epidermis 
and provide resistance to the  physical stresses 
 Stratum granulosum (granular layer): It consists of living cells, these are 
responsible for further synthesis and modification of the proteins involved in 
keratinization. It is 1-3 cells layer in thickness 
  Stratum corneum (horny layer): the corneocytes are rich in protein and low in 
lipid content (hydrophilic nature) are surrounded by a continuous extra cellular 
lipid matrix  
  Malpighian layer ( pigment  layer): the layer whose protoplasm has not yet 
change into horny material  
 Fig No.2: Structure of skin layers 
1.4.3. Dermis 
It lies beneath the epidermis 1.5 - 4 mm thick (thickest of the three layers of the 
skin). It is like home for most of the skin’s structures including sweat glands and oil 
glands, hair follicles, nerve endings, and blood and the lymph vessels. The main 
components of the dermis are collagen and elastin. It stores much of the body’s water 
supply.  
The dermis also contains the scavenger cells from the immune system. In an event 
that a foreign organism tries to pass through epidermis, these cells will engulf and destroy. 
It is an integrated system of fibrous, amorphous and filamentous connective tissue 
that accommodates stimulus induced entrance by nerve, vascular-networks, fibroblasts, 
appendages, mast cells. Its thickness ranges from 2000-3000μm. The principal component 
of the dermis is collagen and it represents 70% of the skin’s dry weight 
1.4.4. Subcutaneous tissue (Connective Tissue)  
The subcutaneous tissue or hypodermis is not actually considered as a true part of 
the structured connective tissue, which comprises of loose textured, fibrous, white, 
connective tissue containing blood and lymph vessels, secretary pores of the sweat gland 
and the cutaneous nerves. Most investigators consider that drug permeating through the 
skin enters the circulatory system before reaching the hypodermis, although the fatty tissue 
could serve as a depot of the drug.        
 1.4.5.Blood and lymph vessels 
Arterioles form a fine network with capillary branches supplying sweat glands, 
sebaceous glands, hair follicles, and the dermis. Lymph vessels form a network through 
the dermis. 
1.4.6. Sensory nerve endings 
Sensory receptors (specialized nerve endings) sensitive to touch, temperature, 
pressure, and pain are widely distributed in the dermis. Incoming stimuli activate different 
types of sensory receptors. The pacinian corpuscle is sensitive to deep pressure. The skin 
is an important sensory organ through which individuals receive information about their 
environment. Nerve impulses, generated in the sensory receptors in the dermis, then to the 
sensory area of the cerebrum where the  sensations  are  perceived. 
1.4.7. Sweat glands 
           These are widely distributed throughout the skin and are most numerous in the 
palms of the hands, soles of the fet, axillae, and groins. They are formed from epithelial 
cells. There are two types of sweat gland. The commonest type opens onto the skin surface 
through tiny pores, and the sweat produced here is clear, watery fluid important in 
regulating body temperature. 
 
                                   1.5. Functions of the skin [19] 
1.5.1. Protection 
The skin forms relatively water proof layer, provided mainly by its epithelium, 
which protects the deeper and more delicate structures. As an important non-specific 
defence mechanism its act as a barrier against: 
 Invasion by micro organism 
 Chemicals 
 Physical agents 
 dehydration 
The epidermis contains specialized immune cells called langerhans cells, which are 
a type of microphage. Due to the presence of the sensory nerve endings in the skin the 
body reacts by reflex action to unpleasant or painful stimuli, protecting it from further 
injury. 
1.5.2. Regulation of body temperature 
             Body temperature remains fairly constant at about 36.8℃ across a wide range of 
environmental temperature ensuring that the optimal range for enzyme activity required 
for metabolism is maintained. In health, variation are usually limited to between 0.5 and 
0.75℃, although it rises slightly in the evening, during exercise and in women just after 
ovulation 
1.5.3. Heat production 
When metabolic rate increases, body temperature rises, and when it decrease body 
temperature falls. Some of the energy diffusion during metabolic activity is in the form of 
heat and the most active organs produced in the body and heat lost to the environment. 
The principal organs involved are 
 Skeletal muscles- contraction of skeletal muscles produces a large amount 
of heat and the more strenuous the muscular exercise, the greater the heat 
produced 
 The liver is very metabolically active and heat is produced as a by-product. 
Metabolic rate and heat production are increased after eating 
 The digestive organs produce heat during peristalsis and during the 
chemical reactions involved in digestion 
1.5.4. Heat loss 
 Most heat loss from the body occurs through the skin. Small amounts are lost in 
expired air, urine, and faeces. Only heat loss through the skin can be regulated. Heat loss 
by the outer routes cannot be controlled.  
            Heat loss through the skin is affected by the difference between body and 
environmental temperatures, the amount of the body surface exposed and the type of 
clothes worn. Air insulates against heat loss when trapped in layers of clothing and 
between the skin and clothing.  
              For this reason several layers of light weight clothes provide more effective 
insulation against low environmental temperatures than one heavy garment. 
1.5.5. Drug transport across skin 
            There are mainly two important layers in the skin epidermis and dermis. Blood 
vessels are profusely distributed beneath the skin in the subcutaneous layer.  
There are two primary mechanisms intended for drug absorption through the skin they are:  
 Intercellular 
 Trans cellular 
       The another most common route of delivery is through the pilosebaceous route. 
Permeation tend to occur through intercellular matrix, but via trans cellular pathway it has 
been shown to provide a quicker alternative route for highly polar molecules.  
           In normal intact skin it is considered that the keratinized corneocytes and the large 
non-polar lipid intercellular cement of the horny layer are the major factors involved in 
maintenance of efficient barrier for drugs. The drug penetration for skin can be improved 
by using organic solvents such as propylene glycol, Di Methyl Shulphoxide (DMSO) and 
surfactants 
             The permeation enhancers alters the barrier properties of the stratum corneum by 
type of mechanism which includes enhancing solubility, partitioning the stratum corneum 
and fluidizing the crystalline structure of the stratum corneum 
             New technologies now allow other drugs to be absorbed via skin. These can be 
used to treat not just the affected areas of the skin but the whole body by systemic route. 
The barrier resides in the outmost layer of the epidermis and the stratum corneum, as 
evidenced by just about equal rates of penetration of chemicals through the isolated 
stratum corneum or whole skin. 
1.6. TRANSDERMAL DRUG DELIVERY SYSTEM 
               The (TDDS) are defined as self-contained, discrete dosage forms which, when 
applied to the intact skin, deliver the drug(s), through the skin, at a controlled rate to the 
systemic circulation. Transdermal drug delivery is a viable administration route for potent, 
low-molecular weight therapeutic agents which cannot withstand the hostile environment 
of gastrointestinal tract and/or subject to considerable first-pass metabolism by the liver. 
 
 
                                                Fig No.3:Transdermal patch 
Transdermal drug delivery systems are topically administered medicaments in the form of 
patches that deliver drugs for systemic effects at a predetermined and controlled rate. A 
transdermal drug delivery device, which may be of an active or a passive design, is a 
device which provides an alternative route for administering medication. These devices 
allow for pharmaceuticals to be delivered across the skin barrier. 
              In theory, transdermal patches work very simply.  A drug is applied in a relatively 
high dosage to the inside of a patch, which is worn on the skin for an extended period of 
time. Through a diffusion process, the drug enters the bloodstream directly through the 
skin. Since, there is high concentration on the patch and low concentration in the blood, 
the drug will keep diffusing into the blood for a long period of time, maintaining the 
constant concentration of drug in the blood flow [20].  
1.6.1. Advantages of TDDS [21] 
   This approach to drug delivery offers many advantages over traditional methods: 
 As a substitute for the oral route 
 Transdermal drug delivery enables the avoidance of gastrointestinal absorption, 
with its associated pitfalls of enzymatic and pH associated deactivation 
 This method also allows for reduced pharmacological dosaging due to the 
shortened metabolization pathway of the transdermal route versus the 
gastrointestinal pathway 
 The patch also permits constant dosing rather than the peaks and valleys in 
medication level associated with orally administered medications. Multi-day 
therapy with a single application. Rapid notification of medication in the event of 
emergency, as well as the capacity to terminate drug effects rapidly via patch 
removal 
1.6.2. Disadvantages of TDDS  
 The drug that requires high blood levels cannot be administered and may even 
cause irritation or sensitization of the skin 
 The adhesives may not adhere well to all types of skin and may be uncomfortable 
to wear 
 High cost of the product is also a major drawback for the wide acceptance of this 
product 
 Properties that influence transdermal delivery diffusion of the medicament from 
the vehicle  
 Penetration through the skin barrier activation of the pharmacological response 
 
 
1.6.3. Pathway of Transdermal Permeation 
The permeation of drugs through the skin includes the diffusion through the intact 
epidermis and through the skin appendages, ie., hair follicles and sweat glands, which 
form shunt pathways through the intact epidermis. However, these skin appendages 
occupy only 0.1% of the total human skin surface and the contribution of this pathway is 
usually considered to be small (with only a few exceptions having been noted). As stated 
above, drug permeation through the skin is usually limited by the Stratum corneum. Two 
pathways through the intact barrier may be identified (Fig No.4) the intercellular lipid 
route between the corneocytes and the transcellular route crossing through the corneocytes 
and the intervening lipids  that is, in both cases the permeant must diffuse at some point 
through the intercellular lipid matrix, which is now recognized as the major determinate of 
percutaneous transport rate[22]. 
 
Fig No.4: Drug Pathway Of Skin 
1.6.4 Kinetics of Transdermal Permeation 
  Knowledge of skin permeation kinetics is vital to the successful 
development of transdermal therapeutic systems. Transdermal permeation of a drug 
involves the following steps:  
 1. Sorption by stratum corneum.  
 2. Penetration of drug through epidermis.  
 3. Uptake of the drug by the capillary network in the dermal papillary layer.  
            This permeation can be possible only if the drug possesses certain physiochemical 
properties. The rate of permeation across the skin is given by 
dQ⁄dt    =   Ps (Cd – Cr)----1 
            Where Cd and Cr are the concentration of the skin penetrant in the donor 
compartment i.e. on the surface of stratum corneum and in the receptor compartment i.e. 
body respectively. Ps is the overall permeability coefficient of the skin tissue to the 
penetrant. This permeability coefficient is given by the relationship  
Ps =DssKs/hs---------2 
              Where Ks is the partition coefficient for the interfacial partitioning of the 
penetrant molecule from a solution medium or a transdermal therapeutic system on to the 
stratum corneum, Dss is the apparent diffusivity for the steady state diffusion of the 
penetrant molecule through a thickness of skin tissues and hs is the overall thickness of 
skin tissues. As Ks, Dss and hs are constant under given conditions the permeability 
coefficient Ps for a skin penetrant can be considered to be constant. From equation (1) it is 
clear that a constant rate of drug permeation can be obtained only when Cd >> Cr i.e. the 
drug concentration at the surface of the stratum corneum Cd is consistently and 
substantially greater than the drug concentration in the body Cr.  
The equation becomes 
dQ/dt =PsCd----------3 
              The rate of skin permeation is constant provided the magnitude of Cd remains 
fairly constant throughout the course of skin permeation. For keeping Cd constant the drug 
should be diffusiond from the device at a rate Rr i.e. either constant or greater than the rate 
of skin uptake Ra i.e. Rr>> Ra. Since Rr>> Ra , the drug concentration on the skin surface 
Cd is maintained at a level equal to or greater than the equilibrium solubility of the drug in 
the stratum corneum Cs .i.e. Cd>>Cs.  
               Therefore a maximum rate of skin permeation is obtained and is given by the 
equation:   
(dQ/dt) m    =    PsCs---------4 
From the above equation it can be seen that the maximum rate of skin permeation 
depends upon the skin permeability coefficient Ps and is equilibrium solubility in the 
stratum corneum Cs. Thus skin permeation appears to be stratumcorneum limited [23]. 
 
Fig No.5: Skin permeation 
1.6.5. Basic Components of Transdermal Drug Delivery Systems 
 1. Polymer matrix or matrices 
 2. The drug  
 3. Permeation enhancers 
 4. Other excipients  
1. Polymer Matrix 
            The Polymer controls the diffusion of the drug from the device. Possible useful 
polymers for transdermal devices are:  
a. Natural Polymers: e.g., cellulose derivatives, Zein, Gelatin, Shellac, 
Waxes, Proteins, Gums and their derivatives, Natural rubber, Starch etc.  
b. Synthetic Elastomers: e.g., polybutadieine, Hydrin rubber, Polysiloxane, 
Silicone rubber, Nitrile, Acrylonitrile, Butyl rubber, Styrenebutadieine 
rubber, Neoprene etc. 
 c. Synthetic Polymers: e.g., polyvinyl alcohol, Polyvinyl chloride, 
Polyethylene, Polypropylene, Polyacrylate,Polyamide ,Polyurea, Polyvinyl 
pyrrolidone, Polymethyl  methacrylate, Epoxy etc.  
 
 
2. Drug 
          For successfully developing a transdermal drug delivery system, the drug should be 
chosen with great care. The following are some of the desirable properties of a drug for 
transdermal delivery.  
        Physicochemical properties 
 The drug should have a molecular weight less than approximately 1000 
Daltons 
 The drug should have affinity for both lipophilic and hydrophilic phases. 
Extreme partitioning characteristics are not conducive to successful drug 
delivery via the skin 
 The drug should have low melting point 
 Along with these properties the drug should be potent, having short half life 
and be non- irritating 
3. Permeation Enhancers 
            These are compounds which promote skin permeability by altering the skin as a 
barrier to the flux of a desired penetrant. These may conveniently be classified under the 
following main headings:  
A. Solvents 
 These compounds increase penetration possibly by swallowing the polar     
pathway and/or by fluidizing lipids. Examples include water alcohols – 
methanol and ethanol; alkyl methyl sulfoxides – dimethyl sulfoxide, alkyl 
homologs of methyl sulfoxide dimethyl acetamide and dimethyl formamide; 
pyrrolid- ones- 2 pyrrolidone, N-methyl, 2-purrolidone; laurocapram 
(Azone), miscellaneous solvents- propylene glycol, glycerol, silicone fluids, 
isopropyl palmitate. 
 
 
 
      B. Surfactants  
These compounds are proposed to enhance polar pathway transport, 
especially of hydrophilic drugs. The ability of a surfactant to alter 
penetration is a function of the polar head group and the hydrocarbon chain 
length.  
 Anionic Surfactants: e.g. Dioctylsulpho - succinate, Sodium lauryl 
sulphate, Decodecyl- methyl sulphoxide etc. Nonionic Surfactants: e.g. 
Pluronic F127, Pluronic F68, etc  
 Bile Salts: e.g. Sodium mstaurocholate, Sodium deoxycholate, Sodium 
tauroglycocholate   
 Binary system: These systems apparently open up the heterogeneous 
multilaminate pathway as well as the continuous pathways.e.g. 
Propylene glycol-oleic acid and 1, 4-butane diollinoleic acid 
 C. Miscellaneous Chemicals 
These include urea, a hydrating and keratolytic agent, N, N-dimethylm-           
toluamide, calcium thioglycolate,  anticholin- ergic agents.  
Some potential permeation enhancers have recently been described but the 
available data on their effectiveness sparse. These include eucalyptol, di-o-
methyl- ßcyclodextrin and   soyabean casein 
4. Other Excipients  
         A. Adhesives: The fastening of all transdermal devices to the skin has so far been 
done by using a pressure sensitive adhesive which can be positioned on the face of the 
device and in the back of the device and extending peripherally.  
  Both adhesive systems should fulfill the following criteria   
 Should  adhere to the skin aggressively, should be easily removed  
 Should not leave an un washable residue on the skin 
 Should not irritate or sensitize the skin 
 
 
 
     The face adhesive system should also fulfill the following criteria 
 Physical and chemical compatibility with the drug, excipients and enhancers 
of the device of which it is a part 
 Permeation of drug should not be affected 
 The delivery of simple or blended permeation enhancers should not be 
affected 
      B. Backing membrane: Backing membranes are flexible and they provide a     
good bond to the drug reservoir, prevent drug from leaving the dosage form through 
the top, and accept printing. 
It is impermeable substance that protects the product during use on the skin e.g. 
metallic plastic laminate, plastic backing with absorbent pad and occlusive base plate 
(aluminium foil), adhesive foam pad (flexible polyurethane) with occlusive base plate 
(aluminium foil disc) etc. 
Desirable features for transdermal patches 
 Composition relatively invariant in use 
 System size reasonable 
 Defined site for application 
 Application technique highly reproducible 
 Delivery is (typically) zero order 
 Delivery is efficient 
1.6.6. Factors affecting transdermal drug delivery 
Skin condition  
The intact skin itself acts as a barrier, but many agents like acids and alkali cross 
the barrier cells and penetrate through the skin. Many solvents open the complex dense 
structure of the horny layer: solvents like methanol and chloroform remove the lipid 
fraction, forming artificial shunts through which drug molecules can pass easily. 
 
 
Skin age  
It is seen that the skin of adults and young ones is more permeable than that of the 
older ones. but there is no dramatic difference. Children show toxic effects because of the 
greater surface area per unit body weight. Thus, potent steroids, boric acid and 
hexachlorophene have produced severe side-effects. 
Physicochemical factors  
Hydration of skin  
Generally, when water saturates the skin, it swells tissues, softens wrinkles on the 
skin and its permeability increases for the drug molecules that penetrate through the skin. 
Temperature and pH of the skin  
The penetration rate varies if the temperature varies and the diffusion coefficient 
decreases as the temperature falls however adequate clothing on the body prevents wide 
fluctuations in temperature and penetration rates. According to pH, only unionized 
molecules pass readily across the lipid membrane, and weak acids and bases dissociate to 
different degrees according to their pH and pKa or pKb values. Thus, the concentration of 
unionized drug in applied phase will determine the effective membrane gradient, which is 
directly related to its pH. 
Environmental factors 
 Sunlight 
  Because of to sunlight, the walls of blood vessels become thinner, leading to 
bruising, with only minor trauma in the sun-exposed areas. Also, pigmentation, the most 
noticeable sun-induced pigment change, is a freckle or solar lentigo. 
 
 
 
Cold season  
The cold season often results in itchy and dry skin. The skin responds by 
increasing oil production to compensate for the weather’s drying effects. A good 
moisturizer will help ease symptoms of dry skin. Also, drinking lots of water can keep 
your skin hydrated and looking radiant. 
Air pollution  
   Air pollution can clog pores and increase bacteria on the face and the surface of 
skin, both of which lead to acne or spots, which affects drug delivery through the skin. 
Invisible chemical pollutants in the air can interfere with the skin’s natural protection 
system, breaking down the skin’s natural oils that normally Dust trap moisture in the skin 
and keep it supple.  
1.6.7. Types of Transdermal Patches [24] 
There are four Major Transdermal Systems:  
1. Single-layer Drug-in-Adhesive   
 
Fig No. 6: Single-layer Drug-in-Adhesive system 
              The Single-layer Drug-in-Adhesive system is characterized by the inclusion of 
the drug directly within the skin-contacting adhesive. In this transdermal system design, 
the adhesive not only serves to affix the system to the skin, but also serves as the 
formulation foundation, containing the drug  and  all the excipients  under a single backing  
film. The rate of diffusion of drug from this type of system is dependent on the diffusion 
across the skin . The intrinsic rate of drug diffusion from this type of drug delivery system 
is defined by 
                                             dQ/Dt = Cr/(1/Pm+1/Pa) 
          Where Cr is the drug concentration in the reservoir compartment and Pa and Pm are 
the permeability coefficients of the adhesive layer and the rate controlling membrane,  
           Pm is the sum of permeability coefficients simultaneous penetrations across the 
pores and the polymeric material. Pm and Pa, respectively, are defined as follows.  
Pm  = Km/rDm/hm 
Pa = Ka/m.Da/ha 
Where Km/r and Ka/m are the partition coefficients for the interfacial partitioning 
of drug from the reservoir to the membrane and from the membrane to adhesive 
respectively, Dm and Da are the diffusion coefficients in the rate controlling membrane 
and adhesive layer, respectively, and hm and ha are the thicknesses of the rate controlling 
membrane and adhesive layer, respectively. 
2. Multi-layer Drug-in-Adhesive 
 
Fig No. 7: Multi-layer Drug-in-Adhesive system 
               The Multi-layer Drug-in-Adhesive is similar to the Single-layer Drug-in-
Adhesive in that the drug is incorporated directly into the adhesive. However, the multi-
layer encompasses either the addition of a membrane between two distinct drug-in-
adhesive layers or the addition of multiple drug-in-adhesive layers under a single backing 
film. 
The rate of drug diffusion in this system is defined by:   
Dq/dt =Ka/r.Da /ha (cr) 
           Where Ka/r is the partition coefficient for the interfacial partitioning of the drug 
from the reservoir layer to adhesive layer. 
 
3. Drug Reservoir-in-Adhesive  
 
Fig No.8: Drug Reservoir-in-Adhesive system 
                The Reservoir transdermal system design is characterized by the inclusion of a 
liquid compartment containing a drug solution or suspension separated from the diffusion 
liner by a semi-permeable membrane and adhesive. The adhesive component of the 
product responsible for skin adhesion can either be incorporated as a continuous layer 
between the membrane and the diffusion liner or in a concentric configuration around the 
membrane. 
The rate of drug diffusion from this drug reservoir gradient controlled system is given by:  
Dq/dt = Ka/r.Da / ha(t).A(ha) 
In the above equation, the thickness of the adhesive layer for drug molecule to 
diffuse through increases with time ha (t). To compensate for this time dependent increase 
in the diffusional path due to the depletion of drug dose by diffusion, the drug loading 
level is also  increased with the thickness of diffusional path A (ha). 
 
 
 
4. Drug Matrix-in-Adhesives 
 
Fig No.9: Drug Matrix-in-Adhesive system 
             The Matrix system design is characterized by the inclusion of a semisolid matrix 
containing a drug solution or suspension which is in direct contact with the diffusion liner. 
The component responsible for skin adhesion is incorporated in an overlay and forms a 
concentric configuration around the semisolid matrix.  
The rate of drug diffusion from this type of system is defined as:  
dQ / dt  = ACpDP½ / 2t 
Where A is the initial drug loading dose dispersed in the polymer matrix and Cp 
and Dp are the solubility and diffusivity of the drug in the polymer respectively. Since, 
only the drug species dissolved in the polymer can diffusion, Cp is essentially equal to CR, 
where CR is the drug concentration in the reservoir compartment. 
 
1.6.8. Limitations of Transdermal Delivery System 
 Higher molecular weight candidates (>500Daltons) fail to penetrate the 
Stratum corneum 
 Drugs with very low or high partition coefficient fail to reach systemic 
circulation 
 High melting drugs are not suitable due to their low solubility both in water 
and fat 
 
 
  Possibility of local irritation at the site of patch application 
 A lag time associated with the  delivery of the drug across the  skin, resulting in 
a delay in onset of action 
 Variation of absorption rate based on site of application 
 Presence of skin diseases 
 Variation in adhesive effectiveness in different individuals 
 
1.7. EVALUATION METHODS25 
The evaluation methods for transdermal dosage form can be classified into following 
types: 
 Physicochemical evaluation  
 In vitro evaluation  
 In vivo evaluation 
1.7.1. Physicochemical evaluation   
1. Interaction studies   
              The drug and the excipients must be compatible with one another to produce a 
product that is stable. The interaction between drug and excipients affect the 
bioavailability and stability of the drug. If the excipients are new and have not been used 
in formulations containing the active substance, the compatibility studies play an 
important role in formulation development. Interaction studies are taken out by Thermal 
analysis, Fourier transform infrared spectroscopy (FTIR), ultra violet (UV) and 
chromatographic techniques by comparing their physicochemical properties like assay, 
melting point, wave numbers, and absorption maxima. 
2. Thickness of the patch 
             The thickness of the drug prepared patch is measured by using a digital 
micrometer at different point of patch and this determines the average thickness and 
standard deviation for the same to ensure the thickness of the prepared patch. 
 
3. Weight uniformity 
             The prepared patches are to be dried at 60°C for 4 h before testing. A specified 
area of patch is to be cut in different parts of the patch and weighed in digital balance. The 
average weight and standard deviation values are to be calculated from the individual 
weights.    
4. Folding endurance 
            A specific area of strip is cut and repeatedly folded at the same place till it broke. 
The number of times the film could be folded without breaking gave the value of folding 
endurance.     
5. Percentage moisture content 
             The prepared patches are to be weighed individually and to be kept in a desiccator 
containing fused calcium chloride at room temperature. After 24 h, the films are to be 
reweighed and the percentage moisture content determined by below formula, 
Percentage moisture content (%) = [Initial weight - Final weight / Final weight] ×100 
6. Percentage moisture uptake 
              The prepared patches are to be weighed individually and to be kept in a 
desiccators containing saturated solution of potassium chloride in order to maintain 84% 
Rhesus factor (RH). After 24 h, the films are to be reweighed and the percentage moisture 
uptake determined by the formula. 
Percentage moisture uptake (%) = (Final weight - Initial weight / initial weight) × 100 
7. Water vapour permeability (wvp) evaluation 
             Water vapour permeability can be determined by a natural air circulation oven. 
The WVP can be determined by the following formula. 
            WVP = W/A  Where, WVP is expressed in g/m2 per 24 h, W is the amount of 
vapour permeated through the patch expressed in g/24 h, A is the surface area of the 
exposure samples expressed in m.    
 
 
 8.Drug content 
            A specified area of patch is to be dissolved in a suitable solvent in specific volume. 
Then, the solution is to be filtered through a filter medium and the drug content analyzed 
with the suitable method (UV or HPLC technique).Then, the average of three different 
samples is taken. 
9. Content uniformity test 
             Ten (10) patches were selected and content determined for individual patches. If 9 
out of 10 patches have content between 85 to 115% of the specified value and one has 
content not less than 75 to 125% of the specified value, then transdermal patches pass the 
test of content uniformity. But if 3 patches have content in the range of 75 to 125%, then 
additional 20 patches are tested for drug content. If these 20 patches have range from 85 to 
115%, then the transdermal patches pass the test.   
10. Flatness test 
           Three longitudinal strips were cut from each film at different portion like one from 
the center, other one from the left side, and another one from the right side. The length of 
each strip was measured, and the variation in length because of non-uniformity in flatness 
was measured by determining percentage constriction, with 0% constriction equivalent to 
100% . 
                                 Flatness  Constriction (%) = I1 - I2 × 100 I1 
Where, I1 = initial length of each strip. I2 = final length of each strip.    
11. Percentage elongation break test   
          The percentage elongation break was determined by noting the length just before the 
break point and determined from the formula. 
                  Elongation percentages = L1 - L2 / L2 × 100   
Where L1 = final length of each strip L2 = initial length of each strip 
 
 
12. Peel Adhesion Properties  
Peel adhesion is the force required to remove all adhesive coating from test 
substrate, its important in transdermal devices because the adhesive should provide 
adequate contact of device with the skin of the adhesive polymer, the type and amount of 
adhesive and polymer composition. It’s tested by measuring the force required to pull a 
single coated tape, applied to substrate, at a 180º angle, No residue on the substrate 
indicates adhesive failure which is desirable for transdermal devices, remnants on 
substrate indicates cohesive failure. Signifying a deficit of cohesive strength in the coating 
as shown in Fig No:10 
 
 
 
Fig No.10: Peel Adhesion Properties 
 
13. Tack Properties  
Tack is the ability of a polymer to adhere to substrate with little contact pressure. It 
is important in transdermal devices which are applied with finger pressure. Tack is 
dependent on the molecular weight and composition of polymer as well as use tackifying 
resins in the polymer.  
 
14.Thumb Tack Test  
This is subjective test in which evaluation is done by pressing the thumb briefly 
into the adhesive experience is required for using test. 
  
 
 
15.Rolling Ball Tack Test  
This test involves measurement of distance travelled by a stainless steel along the 
upward face of adhesive. The diameter of ball is 7/16o inches and it diffusiond on inclined 
track having angle 22.5 or more the distance travelled, less the tacky polymer. Distance 
travelled by ball is measured in inches which determine the tackiness of polymer. It 
determines the softness of adhesive polymer. As shown in Fig No.11 
 
 
 
Fig No.11:Rolling Ball Tack Test 
          
16.Quick-Stick (Or Peel-Tack) Test  
The peel force required to  break the bond between an adhesive and substrate is 
measured by pulling the tape away from the substrate at 90° at a speed of 12 inch/min. The 
force is recorded as the tack value and expressed in ounces (or grams) per inch width with 
higher values indicating increasing tack. As shown in Fig No.12  
 
Fig No.12: Quick-Stick (Or Peel-Tack) Test 
 
 
17.Probe Tack Test  
In this, the tip of probe with defined surface roughness brought in to contact with 
adhesive and when the bond is formed between the adhesive a probe, removal of probe at 
a fixed rateaway from the adhesive which break the bond. The force required to break the 
bond Is recorded as tack and it is expressed in grams as shown in Fig No. 13      
 
Fig No. 13. Probe tack test 
18. Shear strength Properties  
The cohesive strength of an adhesive polymer is determined by this test. The value 
of strength can be affected by the degree of cross linking, the molecular weight, the 
composition of polymer and the amount of tackifiers added. An adhesive coated patch is 
stacked on plate made of stainless steel and specified weight hung from the patch parallel 
to this plat. The time taken to pull off the patch from the plate determines the cohesive 
strength. More the time taken, greater is the shear strength as shown in Fig no14. 
 
 
Fig No.14. Shear strength test 
 
 19. Stability studies 
           Stability studies were conducted according to the International Conference on 
Harmonization (ICH) guidelines by storing the TDDS samples at 40 ± 0.5°C and 75 ± 5% 
RH for 6 months. The samples were withdrawn at 0, 30,    60, 90 and 180 days and 
analyzed suitably for the drug content. 
1.7.2. In vitro evaluation of TDDS [26] 
   In vitro drug diffusion studies 
 The paddle over disc method (USP apparatus) can be employed for assessment of 
the diffusion of the drug from the prepared patches. Dry films of known thickness were 
cut into definite shape, weighed, and fixed over a glass plate with an adhesive. The glass 
plate was then placed in a 500 ml of the dissolution medium or phosphate buffer (pH 7.4), 
and the apparatus was equilibrated to 32 ± 0.5°C. The paddle was then set at a distance of 
2.5 cm from the glass plate and operated at a speed of 50 rpm. Samples (5 ml aliquots) can 
be withdrawn at appropriate time intervals up to 24 h and analyzed by UV 
spectrophotometer or HPLC. The experiment was performed in triplicate and the mean 
value calculated. 
            Flux was determined directly as the slope of the curve between the steady-state 
values of the amount of drug permeated (mg cm2) versus time in hours, and permeability 
coefficients were deduced by dividing the flux by the initial drug load (mg cm2).    
 
 2. a. Literature  review on  Azadirachta indica A.juss (Neem)  
 
Mohammad A. Alzohairy et al., (2016) studied the therapeutic role of Azadirachta indica 
(Neem) and their active constituents in diseases prevention and treatment. Neem (Azadirachta 
indica) is a member of the Meliaceae family and its role as health-promoting effect is 
attributed because it is rich source of antioxidant. It has been widely used in Chinese, 
Ayurvedic, and Unani medicines worldwide especially in Indian Subcontinent in the 
treatment and prevention of various diseases. its constituents play role in the scavenging of 
free radical generation and prevention of disease pathogenesis 
  
Chhibber.S et al., (2014) reviewed  the medicinal and therapeutic use of Azadirachta indica, 
a fast growing, evergreen tree found commonly in India, Africa and America. Neem is one of 
the most useful traditional medicinal plant in India. It is a highly esteemed tree with several 
beneficial properties and applications, especially known for its incredible therapeutic and 
ethnomedicinal values for mankind. It has been used in different medicinal systems: 
Ayurveda, unani, homeopathic medicine, therefore considered as cynosure of modern 
medicine 
Soniya Adyanthaya et al., (2014) evaluated the antimicrobial potential of the extracts of the 
twigs of Azadirachta indica (Neem). An in vitro study of various medicinal plants have been 
used since ancient times in daily life to treat diseases all over the world. Almost every part of 
the Azadirachta indica A. Juss (syn. Melia azadirachta) tree commonly known as neem has 
been used for years to treat a number of human diseases. As neem is known to possess 
antimicrobial activity against a number of organisms 
 
 
 
 
 
 Jaya vikas kurhekar et al., (2013)  analysed the aqueous and acetone extracts of neem a for 
inherent components, anti-microbial activities against common pathogens and compared with 
standard antibiotics 
 
Imam Hashmat et al., (2012) reviewed that Azardirachta indica A juss is a nature’s drug 
store. This review gives a bird’s eye view mainly on the biological activities of the neem and 
some of their compounds isolated, pharmacological actions of the neem extracts, clinical 
studies and medicinal applications of neem along with their safety evaluation 
Sugumari  Elavarasu et al.,  (2012)  evaluated anti-plaque microbial activity of Azadirachta 
indica (neem oil) in vitro: The use of Azadirachta indica (Indian neem) is considered as the 
plants have a wide spectrum of bioactivity. They are used as antibacterial, antifungal, and 
anticancerous agents. The purpose of the study was to utilize this Indian herb in the reduction 
of microorganisms 
Kausik Biswas et al., (2011) reviewed that biological activities and medicinal properties of 
neem (Azadirachta indica A. Juss) is perhaps the most useful traditional medicinal plant in 
India. Each part of the neem tree has some medicinal property and is thus commercially 
exploitable. During the last five decades, apart from the chemistry of the neem compounds, 
considerable progress has been achieved regarding the biological activity and medicinal 
applications of neem. It is now considered as a valuable source of unique natural products for 
the development of medicines against various diseases  
 
Alok Maithani et al., (2011) reviewed Azadirachta indica (Neem) leaf  is one of the most 
revenue releasing plant grown in India because of several phytoconstituents present in it and 
also due to a number of pharmacological activities associated with it. The present review 
highlights a literature on taxonomical, botanical, phytoconstituents, and pharmacological 
discussion on Azadirachta indica leaves 
 
 
 
 
  A. Biu et al., (2009) done phytochemical screening of Azadirachta indica (Neem) 
(Meliaceae). Air dried aqueous-extract has been subjected to screen for some active chemical 
constituents. Saponins had high scores in the extract, tannins and glycosides indicated 
moderate scores, while alkaloids, terpenes, flavonoids, reducing sugars, pentoses and whole 
carbohydrates showed low scores. Anthraquinones, ketones and mono saccharides were not 
detected from the extract 
Mary Ndung'u et al., (2004) studied that Neem (Azadirachta indica A. Juss) is known to be 
an important source of triterpenoids; and multipurpose tree species native to the dry forest 
zones of the Asian subcontinent including India, Sri Lanka, Pakistan, Bangladesh, Malaysia, 
Myanmar and Thailand. The tree is found both cultivated and growing in its natural habitat in 
this zones and it has been transferred to many of the warmer parts of the world. 
 
 
 
 
 
2. LITERATURE REVIEW 
              2. b. Literature Review on TDDS  
 L. Karpagavalli et al., (2017) formulated and evaluated Transdermal Patches of      
Curcumin. The work showed that drug of ayurvedic origin can be utilized in a better 
form. The films formed using HPMC were thin, flexible and smooth and these patch 
with permeation enhancer showed maximum enhanced efficacy for incorporation into 
modern dosage forms. The sustained release of curcumin from transdermal patches can 
minimize the frequent administration of conventional curcumin dosage forms 
 
 Suneetha Cherukuri et al., (2017) formulated and evaluated of transdermal drug 
delivery of Topiramate. On the basis of results obtained from the physical evaluation 
and ex vivo studies, the patches containing the polymers, Eudragit L 100 and 
polyvinylpyrrolidone, with oleic acid as the penetration enhancer were considered as 
the best formulations for the transdermal delivery of (TPM) 
 
 Deepak Kumar Patel et al., (2016) formulated transdermal patch of curcumin with the 
main objective to minimize the side effects and maximize the therapeutic efficacy. The 
formulations were evaluated for weight variation, moisture uptake, thickness, moisture 
content and folding endurance 
  
 Shashi Kumar Yadav et al., (2013) formulated and evaluated of transdermal patch 
of Ayurvedic  Antirheumatic Drug using  Different polymers . 4 - day skin 
permeation study shows 81.44% release of drug from the formulation 7 containing 
polymers HPMC, Ethyl cellulose and PEG-6000 (10:10:1). Hence, this formula was 
considered to be the optimized formulation with good physicochemical properties, 
skin compatibility, and sustained drug release 
 
 
 
  Sunil R. Rathva et al., (2012) carried out a review on Herbal transdermal patches. It 
has been found that drugs from herbal origin can be utilized with enhanced   efficacy 
by incorporating in transdermal patches.   Herbal transdermal patches aids to quit 
smoking, relieve stress, increase sexuality, insect repellant patches, detoxification, 
male energizer, postpone menopause are available in market 
 
 Kansagra Hemanh et al., (2012) formulated and evaluated transdermal patch of  
Sertaconazole nitrate. The permeation studies illustrated that the ratio of polyvinyl 
pyrrolidone and ethyl cellulose 1:5 showed good controlled release. Higuchi and 
Korsmeyer-Peppas models were used for optimizing the formulation 
 
 Santosh S Bhujbal et al., (2011) developed a novel herbal formulation in the 
management of diabetes .The weight of transdermal patches of M. charantia (2 cm2; 
10 mg/ patch) and was found to be 0.03 gm. Thickness of patches of M. charantia (2 
cm2; 10 mg/patch) was found to be satisfactory. The percentage release of active 
constituents from transdermal patches of M.charantia (2 cm2; 10 mg/ patch) was 
found to be 47.59% in 10% hydroalcoholic phosphate buffer pH 7.4 at the end of 6 h  
 
 Sarswathi R et al., (2010) formulated and evaluated transdermal patches of 
Curcumin. The in - vitro permeation studies of patches was carried out using 0.5% 
Sodium Lauryl Sulphate solution in the receptor compartment with their different 
patches, F1, F2 and F3 using HPMC and EC bring the satisfactory release of 
curcumin. The cumulative percentage drug release of patch F1-82.20%, F2-74.06% 
and F3-68.27%. The release kinetics was evaluated making by use of Zero order, first 
order, Higuchi’s diffusion and Korsemeyer-Peppas equation. The drug release 
through transdermal patches of curcumin followed Zero order kinetics 
 
 
 
3. AIM AND OBJECTIVE 
 
 
3.1. Aim 
 
   To prepare and evaluate Transdermal  Patch of  Aqueous extract of     
   Azadirachta indica A. juss using  different polymers 
 
3.2. Objective 
 To convert the herbal extract into a novel dosage form 
 
 To provide a direct entry of aqueous extract into the systemic circulation to give 
sustained action 
 To develop a novel topical formulation of aqueous extract of neem leaves for the 
effective treatment of Skin infections  
  
 
4. PLAN OF THE WORK 
 Literature Survey 
 Selection of Herb 
 Procurement of dried powder of leaves of Azadirachta indica A. juss. 
 Phytochemical evaluations 
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 Trial batches for Transdermal Patches (extract : polymer in different ratio) 
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 Percent moisture absorption 
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 In- vitro Evaluation 
 
 Anti-Microbial screening  studies 
 Release kinetics 
 Ex-vivo studies 
 Stability studies 
 Results and discussions 
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Fig No.15: Authentication of plant 
 
 
 
 5.1. PLANT PROFILE 
 
Fig No.16: Leaves of Azadirachta indica A. Juss. 
5.1.1. Scientific Classification [28] 
Kingdom  :  Plantae 
Order   : Sapindales 
Family  : Meliaceae 
Genus   :  Azadirachta 
Species   : indica 
Common name          :           Neem 
            English                       :            Neem 
            Tamil                          :           Veppai, vembu,sengumaru 
            Hindi                          :            Neem            
5.1.2. Description 
Colour  : Green  
Taste   : Bitter 
Odour   : Pungent 
5.1.3. Synonyms 
 Azadirachta indica var. minor 
 Azadirachta indica var. siamensis 
 Azadirachta indica subsp. Vartakii 
 Melia azadirachta L. 
 Melia indica (A. Juss.) 
5.1.4. Habitat [29] 
Most well-known for its insecticidal properties, the neem tree (Azadirachta indica) grows 
as a statuesque woodland, shade and crop tree in many tropical and subtropical countries. As 
well as its many practical uses, it's also ornamental, bearing 10-inch-long, fragrant, white, spring 
flowers. Neem tree's habitats include its natural growing range and the many areas where 
humans have planted it, taking advantage of its tolerance for tough conditions. It is hardy in U.S. 
Department of Agriculture plant hardiness zones 10 to 12. 
5.1.5. Vernacular names of Azadirachta indica A. Juss. 
 Tamil - Veppai (฀฀฀฀฀฀), Sengumaru 
 English - Margosa, Neem Tree 
 Hindi – Neem 
 Kannada – Bevu 
 Malayalam – Aryaveppu 
 Sanskrit - Arishta, Pakvakrita, Nimbaka 
 Telugu – Vepa 
  
5.1.6. Uses [30,31] 
 
Azadirachta indica, commonly known as neem, has attracted worldwide prominence in 
recent years, owing to its wide range of medicinal properties. Neem has been extensively 
used in Ayurveda, Unani and Homoeopathic medicine and has become a cynosure of modern 
medicine. Neem elaborates a vast array of biologically active compounds that are chemically 
diverse and structurally complex. More than 140 compounds have been isolated from 
different parts of neem. All parts of the neem tree - leaves, flowers, seeds, fruits, roots and 
bark have been used traditionally for the treatment of inflammation, infections, fever, skin 
diseases and dental disorders. The medicinal utilities have been described especially for 
neem leaf. Neem leaf and its constituents have been demonstrated to exhibit 
immunomodulatory, anti-inflammatory, antihyperglycaemic, antiulcer, antimalarial, 
antifungal, antibacterial, antiviral, antioxidant, antimutagenic and anticarcinogenic 
properties. 
5.1.7.Pharmacological activity[32] 
 Analgesic agent 
 Antipyretic agent 
 Antimicrobial activity 
 Antibacterial activity 
 Antifungal activity 
 Antiviral activity 
 Contraceptic 
 Hepatoprotective 
 Anti-hyper glycemic agent 
5.1.8. Chemical constituents [33,34] 
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 5.2. EXCIPIENT PROFILE [35,36] 
5.2.1. Pectin 
 Pectin is structural hetero-polysaccharides contained in the primary cell walls of 
terrestrial plants. Pectin is a naturally occurring biopolymer that is finding increasing 
applications in the pharmaceutical and biotechnology industry. It has been used successfully for 
many years in the food and beverage industry as a thickening agent, a gelling agent and a 
colloidal stabilizer. Pectin also has several unique properties that have enabled it be used as a 
matrix for the entrapment and or delivery of a variety of drugs, proteins and cells. This review 
will first describe the source and production, chemical structure and general properties of pectin. 
The methods of gel formation and properties of the gels will then be discussed. 
Physical properties  :  White to light brown powder  
Chemical Structure  : 
 
Fig No.17: Pectin 
 
Molecular weight  :  60,000-130,000 g/ mol 
Uses    :  Gelling agent, thickening agent, stabilizer in  
       Food 
 
5.2.2. Sources of Pectin 
 Apples – 1 to 1.5% 
 Apricot – 1% 
 Cherries – 0.4% 
 Oranges – 0.5 to 3.5% 
 Carrots approx – 1.4% 
 Citrus peels – 53% 
5.2.3. General properties of Pectin 
 Pectin is a natural polymer. Pectin is soluble in pure water. Monovalent cation (alkali 
metal) salts of pectinic and pectic acids are usually soluble in water, di- and trivalent cations salts 
are weakly soluble or insoluble. Dry powdered pectin, when added to water, has tendency to 
hydrate very rapidly, forming clumps. These crumps consist of semi dry packets of pectin 
contained in an envelope of highly hydrated outer coating. Further solubilisation of such cramps 
is very slow. Dilute pectin solutions are Newtonian but a moderate concentration, they exhibit 
the non-Newtonian, pseudo plastic behavior characteristics. As with solubility, the viscosity of a 
pectin solution is related to the molecular weight, concentration of the preparation, and the pH 
and presence of counter ions in the solution. Viscosity, solubility and gelation are generally 
related. For example, factors that increase gel strength will increase the tendency to gel, decrease 
solubility, and increase viscosity, and vice versa. 
5.2.4. Pharmaceutical uses of pectin 
 Pectin has applications in the pharmaceutical industry. Pectin favorably influences 
cholesterol levels in blood. Consumption of at least 6g/day of pectin is necessary to have 
a significant effect in cholesterol reduction 
 Pectin acts as a natural prophylactic substance against poisoning with toxications. It has 
been shown to effective in removing lead and mercury from the gastrointestinal tract and 
respiratory organs 
 Pectin injected intravenously, shortens the coagulation time of drawn blood, thus being 
useful in controlling hemorrhage or local bleeding 
 Pectin and combinations of pectin with other colloids have been used extensively to treat 
diarrheal diseases, especially in infants and children 
 Pectin reduces rate of digestion by immobilizing food components in the intestine. This 
results in less absorption of food 
 Pectin hydrogels have been used in tablet formulations as a binding agent matrix tablet 
formulations. HM-pectin’s for their potential value in controlled diffusion matrix 
formulations. The application of a binary polymer system, (i.e) HM-pectin and 
hydroxypropyl methylcellulose 
 Pectin beads prepared by the ionotropic gelation method were used as a sustained 
diffusion drug delivery system 
 Pectin has a promising pharmaceutical uses and is presently considered as a carrier 
material in colon-specific drug delivery systems ( for systemic action or a topical 
treatment of diseases such as ulcerative colitis, crohn’s disease, colon carcinomas) 
 Pectin is an interesting candidate for pharmaceutical use, e.g. as a carrier of variety of 
drugs for controlled diffusion applications. Many techniques have been used to 
manufacture the pectin-based delivery systems, especially ionotropic gelation and gel 
coating 
5.3. Sodium alginate 
Nonproprietary Names 
 BP            :  Sodium alginate 
 PhEur            : Natrialginas 
 USPNF         :           Sodium alginate 
 Synonyms 
 Algin; alginic acid, sodium salt; E401; Kelcosol; Keltone; Protanal; sodium     
       polymannuronate. 
 
 
 5.3.1. Structure of Sodium alginate 
 
 
                                              Fig No.18: Sodium alginate 
 
Chemical Name and CAS Registry Number 
 Sodium alginate [9005-38-3]. Sodium salt of alginic acid, which is a mixture of 
polyuronic acids composed of residues of D-mannuronic acid and L-guluronic acid. The 
block structure and molecular weight of sodium alginate samples have been investigated 
5.3.2. Functional Category 
 Stabilizing agent; suspending agent; tablet and capsule disintegrant; tablet binder; 
viscosity increasing agent. 
5.3.3. Applications in Pharmaceutical Formulation or Technology 
 Sodium alginate is used in a variety of oral and topical pharmaceutical formulations. In 
tablet formulations, sodium alginate may be used as both a binder and disintegrant; it has 
been used as a diluent in capsule formulations. Sodium alginate has also been used in the 
preparation of sustained-diffusion oral formulations since it can delay the dissolution of a 
drug from tablets, capsules, and aqueous suspensions. 
In topical formulations, sodium alginate is widely used as a thickening and suspending 
agent in a variety of pastes, creams and gels and as a stabilizing agent for oil-in-water 
emulsions. Recently, sodium alginate has been used for the aqueous microencapsulation of 
drugs, in contrast with the more conventional microencapsulation techniques which use 
organic solvent systems. It has also been used in the formation of nanoparticles.  
    
The adhesiveness of hydrogels prepared from sodium alginate has been investigated and 
drug diffusions from oral mucosal adhesive tablets, and buccal gels, based on sodium 
alginate have been reported. Other novel delivery systems containing sodium alginate include 
ophthalmic solutions that form a gel in-situ when administered to the eye; and in- situ 
forming gel containing paracetamol fororal administration; and a freeze-dried device 
intended for the delivery of bone-growth factors Hydrogel systems containing alginates have 
also been investigated for delivery of proteins and peptides.  
 
Therapeutically, sodium alginate has been used in combination with an H2-receptor 
antagonist in the management of gastro esophageal reflux, and as a haemostatic agent in 
surgical dressings. Alginate dressings, used to treat exuding wounds, often contain significant 
amounts of sodium alginate as this improves the gelling properties. Sponges composed of 
sodium alginate and chitosan produce a sustained drug diffusion and may be useful as wound 
dressings or as tissue engineering matrices. Sodium alginate is also used in cosmetics and 
food products. 
     5.3.4. Description 
 Sodium alginate occurs as an odourless and tasteless, white to pale yellowish-brown 
coloured powder. 
5.3.5. Typical Properties 
Acidity/alkalinity: pH 7.2 for a 1% w/v aqueous solution. 
Solubility 
 Practically insoluble in ethanol (95%), ether, chloroform, and ethanol/water mixtures in 
which the ethanol content is greater than 30%. Also, practically insoluble in other organic 
solvents and aqueous acidic solutions in which the pH is less than 7. Slowly soluble in water, 
forming  a viscous  colloidal solution. 
 
Viscosity (dynamic) 
 Various grades of sodium alginate are commercially available that yield aqueous 
solutions of varying viscosity. Typically, a 1% w/v aqueous solution, at 200C, will have a 
viscosity of 20-400 m Pas (20-400cP). Viscosity may vary depending upon concentration, 
pH, temperature, or the presence of metal ions. Above pH 10, viscosity decreases. 
5.3.6. Stability and Storage Conditions 
 Sodium alginate is a hygroscopic material, although it is stable if stored at low relative 
humidities and a cool temperature. 
 Aqueous solutions of sodium alginate are most stable at pH 4-10. Below    pH 3, alginic 
acid is precipitated. A 1% w/v aqueous solution of sodium alginate exposed to differing 
temperatures had a viscosity 60-80% of its original value after storage for 2 years. Solutions 
should not be stored in metal containers. 
 Sodium alginate solutions are susceptible on storage to microbial spoilage, which may 
affect solution viscosity. Solutions are ideally sterilized using ethylene oxide, although 
filtration using a 0.45µm filter also has only a slight adverse effect on solution viscosity.  
Heating sodium alginate solutions to temperatures above 700C causes depolymerization with 
a subsequent loss of viscosity. Autoclaving of solutions can cause a decrease in viscosity, 
which may vary depending upon the nature of any other substances present. Gamma 
irradiation should not be used to sterilize sodium alginate solutions since this process 
severely reduces solution viscosity. 
 
 Preparations for external use may be preserved by the addition of 0.1% chlorcresol, 0.1% 
chloroxylenol or parabens. If the medium is acidic, benzoic acid may also be used. The bulk 
material should be stored in an airtight container in a cool, dry place. 
Incompatibilities 
 Sodium alginate is incompatible with acridine derivatives, crystal violet, phenyl mercuric 
acetate and nitrate, calcium salts, heavy metals, and ethanol in concentrations greater than 
5%. Low concentrations of electrolytes cause an increase in viscosity but high electrolyte 
concentrations cause salting-out of sodium alginate 
 
Safety 
 Sodium alginate is widely used in cosmetics, food products, and pharmaceutical 
formulations, such as tablets and topical products, including wound dressings. It is generally 
regarded as a nontoxic and non irritant material, although excessive oral consumption may be 
harmful. A study in five healthy male volunteers fed a daily intake of 175 mg/kg body-
weight of sodium alginate for 7 days, followed by a daily intake of 200 mg/kg body-weight 
of sodium alginate for a further 16 days, showed no significant adverse effects. 
 The WHO has not specified an acceptable daily intake for alginic acid and alginate salts 
as the levels used in food do not represent a hazard to health. 
 Inhalation of alginate dust may be irritant and has been associated with industrial-related 
asthma in workers involved in alginate production. However, it appears that the cases of 
asthma were linked to exposure to seaweed dust rather than pure alginate dust. 
Handling Precautions 
 Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Sodium alginate may be irritant to the eyes or respiratory system if inhaled as dust. 
So Eye protection, gloves and a dust respirator are recommended. Sodium alginate should be 
inhaled in a well-ventilated environment. 
5.4. Glycerin 
5.4.1. Nonproprietary Names 
BP :  Glycerol 
PhEur :  Glycerolum 
5.4.2. Synonyms 
Croderol; E422; glycerine; Glycon G-100; Kemstrene; Optim; Pricerine; 1,2,3- 
propanetriol; trihydroxypropane glycerol. 
5.4.3. Chemical name 
Propane 1, 2, 3-triol. 
5.4.4. Empirical Formula 
C3H8O3 
5.4.5.Molecular Weight 
92.09 
5.4.6. Structural Formula 
 
GLYCEROL 
5.4.7. Description 
Its a clear, colorless, odourless, viscous, hygroscopic liquid, it has a sweet taste, 
approximately 0.6times as sweet as sucrose. 
5.4.8. Functional category 
Antimicrobialpreservative,emollient,humectant,plasticizer,solvent. 
5.4.9. Typical properties 
 Melting point :  17.80C 
 Solubility  : Soluble in water, methanol 
5.4.10. Applications in Pharmaceutical Technology 
It is used in a wide variety of pharmaceutical formulations including oral, ophthalmic, 
topical & parenteral preparations. In topical pharmaceutical            formulations and cosmetics, 
it is used primarily for its humectant & emollient properties. In parenteral formulations it is used 
mainly as a solvent. In oral solutions, glycerin is used a solvent, sweetening agent, antimicrobial 
preservative and viscosity increasing agent. It is also used as a plasticizer and in film coatings. It 
is additionally used in topical formulation such as creams and emulsions. It is used as a 
plasticizer of gelatin in the production of soft-gelatin capsules and gelatin suppositories. It is 
employed as a therapeutic agent in a variety of clinical applications, and is also used as a food 
additive. 
 
5.4.11. Stability and storage conditions 
It is hygroscopic.  Pure glycerin is not prone to oxidation by the atmosphere under 
ordinary storage conditions but it decomposes on heating, with the evaluation of toxic acrolein. 
Mixture of glycerin with water, ethanol & propylene glycol are chemically stable.It may 
crystallize if stored at low temperatures; the crystals do not melt until warmed to 20oC. It should 
be stored in an airtight container, in a cool, dry place. 
 
5.5. Dimethyl Sulfoxide 
5.5.1. Non-proprietary Names 
BP  :  Dimethyl sulfoxide 
PhEur :  Dimethylis sulfoxidum 
USP  :  Dimethyl sulfoxide 
5.5.2. Synonyms 
Deltan; dimexide; dimethyl sulphoxide; DMSO; Kemsol; methylsulfoxide; 
Rimso-50; sulphinyl bismethane 
 
5.5.3. Chemical Name and CAS Registry Number 
Sulfinyl bismethane [67-68-5] 
 
5.5.4. Empirical Formula and Molecular Weight 
C2H6OS M.W: 78.13 
5.5.5. Structural Formula 
 
 
 
 
 
 
5.5.6. Functional Category 
Penetration enhancer; solvent. 
 
 
 
5.5.7. Applications in Pharmaceutical Formulation or Technology 
Dimethyl sulfoxide is a highly polar substance that is aprotic, therefore lacking acidic and 
basic properties. It has exceptional solvent properties for both organic and inorganic 
components, which are derived from its capacity to associate with both ionic species and neutral 
molecules that are either polar or polarizable. Dimethyl sulfoxide enhances the topical 
penetration of drugs owing to its ability to displace bound water from the stratumcorneum ; this 
is accompanied by the extraction of lipids and configurational changes of proteins. The 
molecular interactions between dimethyl sulfoxide and the stratum corneum, as a function of 
depth and time, have been described. Much of the enhancement capacity is lost if the solvent is 
diluted. Increases in drug penetration have been reported with dimethyl sulfoxide concentrations 
as low as 15%, but significant increases in permeability generally require concentrations higher 
than 60–80%. Furthermore, while low molecular weight substances can penetrate quickly in to 
the deep layers of the skin, the appreciable transport of molecules with a molecular weight of 
more than 3000 is difficult. The use of dimethyl sulfoxide to improve transdermal delivery has 
been reported for cyclosporin,timolol, and a wide range of other drugs. Dimethyl sulfoxide has 
also been used in the formulation of an injection containing allopurinol. It has also been 
investigated for use in an experimental parenteral preparation for the treatment of liver tumors. 
In paint formulations of idoxuridine, dimethyl sulfoxide acts both as a solvent to increase drug 
solubility and a means of enabling penetration of the antiviral agent to the deeper levels of the 
epidermis. 
5.5.8. Typical Properties 
Boiling point 
189°C 
Dielectric constant 
48.9 at 20°C 
Solubility 
 Miscible with water with evolution of heat; also miscible with   ethanol(95%), ether and 
most organic solvents; immiscible with paraffins, hydrocarbons. Practically insoluble in 
acetone, chloroform, ethanol (95%), and  ether. 
Vapor pressure 
0.37 mm at 20°C 
Viscosity (dynamic) 
             1.1mPa s (1.1 cP) at 27°C 
5.5.9. Stability and Storage Conditions 
Dimethyl sulfoxide is reasonably stable to heat but upon prolonged reflux it decomposes 
slightly to methyl mercaptan and bismethyl thio methane. This decomposition is aided by acids, 
and is retarded by many bases. When heated to decomposition, toxic fumes are emitted.  
At temperatures between 40–60°C, it has been reported that dimethyl sulfoxide suffers a 
partial breakdown, which is indicated by changes in physical properties such as refractive index, 
density, and viscosity. Dimethyl sulfoxide should be stored in airtight, light-resistant 
containers.The PhEur 2005 states that glass containers should be used. Contact with plastics 
should be avoided. 
 
 
 
 
 
 
 
        6. MATERIALS AND METHODS 
 
6.1. List of Chemicals 
                                                  Table No.1. List of Chemicals                                                  
 
 
 
 
6.2. List of Equipments 
                                          
 
                                                   Table No.2. List of equipm 
 
 
 
S. No. Chemical Name Company Name 
1.  Pectin Loba, Mumbai 
2.  Sodium alginate Kemphasol, Bombay 
3.  DMSO Merck Limited, Mumbai 
4.  Glycerin Merk Limited, Mumbai 
5.  Potassium dihydrogenortho 
phosphate Microfine Chemicals, New Delhi 
6.  Sodium hydroxide Microfine Chemicals, New Delhi 
S.No. Name of Equipment Name of Manufacturer Purpose 
1. Dessicator - Moisture content 
studies 
2. Digital Vernier caliper - Patch thickness Studies 
3. Electronic balance Sortorius, Germany Weighing purpose 
4. Digital pH meter Elico Ltd, AP, India Surface pH study 
5. 
 
Fourier transform Infrared 
Spectrometer Perkin-Elmer, USA Compatibility studies 
6. Magnetic Stirrer 
ROTEK, 
W.Vengola, Kerala, 
India 
Diffusion Studies 
7 UV Spectrophotometer Shimadzu 1700, Japan 
Determination of 
Absorption maxima & 
concentration of active 
substances 
   6.3. Preformulation Studies 
 
 Preformulation testing is the first step in the rational development of 
dosage forms of drugs substance. It can be defined as an investigation of physical and 
chemical properties of a drug substance alone and when combined with excipients. The 
overall objective of preformulation testing is to generate information useful to the 
formulator in developing stable and bioavailable dosage forms that can be man produced. 
The following Preformulation studies are carried out 
 Finding the absorption maxima 
 Physical appearance 
 Solubility 
 Standard curve 
 Infrared spectroscopy studies (compatibility studies) 
6.4. Finding the absorption maxima (λ  max) 
The absorption maxima was found for identification of drug. Ultraviolet Visible 
spectrophotometry has been used to obtain specific information on the chromophoric part 
of the molecules. Organic molecules in solutions when exposed to light in the Visible/ 
Ultraviolet region of the spectrum absorb light of particular wavelength depending on the 
type of electronic transition associated with the absorption. 
 The extract solution (5, 10, 15, 20, 25 μg/ml) in distilled water was taken in a 
standard cuvette and scanned in the range of 200-800 nm in UV spectrophotometer. It 
exhibits maxima at 382 nm. Therefore, further all measurements were taken at 382 nm. 
6.5.  Collection of Azadirachta indica A Juss. leaves 
 Azadirachta indica A Juss. leaves were collected from Periyar College of 
Pharmaceutical Sciences campus, Tiruchppalli, Tamilnadu. Collected leaves were 
authenticated by Botanist, Dept. of Botany, National College, Trichy. Leaves were cleaned 
and shade dried at room temperature.  
6.6. Extraction of leaves of Azadirachta indica A Juss.[37] 
 The shade dried leaves were subjected to size reduction and passed in to sieve no 
20 and then 40. About 500g of the dried powder was extracted continuously in Soxhlet 
apparatus with petroleum ether for 24 hrs to remove the waxy materials. Then it was 
extracted with distilled for 72h. After 72h, the water substance was evaporated to obtain 
the crude extract (7.4%w/v). The extract was dried under vacuum oven. 
  
                  Fig No:19. Soxhylation 
 
6.7.  Phytochemical Studies [38,39] 
 
 
The AE (Aqueous Extract) was subjected to phytochemical studies to find out the 
presence and absence of constituents. 
                                                   
 
 
 
 
 
 
 
 
 
Table No.3:   Phytochemical Tests 
 
EXPERIMENT OBSERVATION INFERENCE 
Test for Alkaloids 
1.Dragendroff’s test: 
The extract was treated 
withDragendroff’s reagent 
(potassium bismuth iodide 
solution) 
 
 
Orange brown Precipitate 
was formed 
 
 
Presence of alkaloids 
2.Mayers’ reagent’s: 
The extract was treated 
with Mayer’s (potassium 
mercuric iodide solution) 
reagent 
 
Precipitate formed 
 
Presence of alkaloids 
3.Wagner’s reagent: 
The extract was treated 
with wagner’s reagent 
(iodide and potassium 
triiodide solution) 
 
Reddish brown Precipitate 
was formed 
 
Presence of alkaloids 
Test for Glycosides 
1.Brontragers test: 
To the extract add dilute 
H2SO4 and filtered. Filtrate 
was extract with little 
chloroform layer was 
separated out and add equal 
volume of dilute NH3. 
 
 
Red colour observed in 
ammonical layer 
 
 
 
Presence of glycosides 
Test for Saponin glycosides 
1.Foam test: 
Shake the extract with 
water. 
 
Foam was produced/formed 
 
Presence of saponin Glycosides 
Test for Tannins and Phenolic compounds 
1.Ferric chloride test: 
To the aqueous extract few 
drops of ferric chloride 
solution were added 
 
Dark black colour formed 
 
Presence of tannins and phenolic 
compounds 
2.Bromine water test: 
To the aqueous extract is 
treated with bromine water 
 
Discoloration of bromine 
Water 
 
 
 
Presence of tannins and phenolic 
compounds 
3.KMnO4test: 
To the aqueous extract is 
treated with dilute KMnO4. 
 
Discoloration of solution 
 
Presence of tannins and phenolic 
compounds. 
 
 
 
Test for Reducing sugar 
1.Benedict’s test: 
 0.5ml of extract solution 
1ml of water 5 to 8 drops of 
fehlings solution was 
added. 
 
No brick red precipitate 
 
Absence of reducing sugar 
Test for Amino acids 
1.Ninhydrin test: 
The aqueous extract is 
heated 
with 5%ninhydrin solution 
on 
boiling water bath for 10 
min. 
 
 
No purple colour formed 
 
 
Presence of amino acids 
2.The aqueous extract is 
treated with solution  
sodium hydroxide  and lead 
acetate solution and boiled 
 
No black precipitate is 
formed 
 
Presence of amino acids 
 
Test for Flavonoids 
1.Shinoda test: 
To the methanol extract add 
potassium hydroxide 
solution and then 10% 
ammonia. 
 
Yellow colour Precipitate 
formed. 
 
Presence of flavonoids 
2.To the ethanol extract, 
add few drops of Lead 
acetate solution. 
 
Yellow colour Precipitate 
formed. 
 
Presence of flavonoids. 
Test for Terpenoids 
1.4gm of extract was 
treated with 0.5ml of acetic 
anyhydride and 0.5ml of 
chloroform and added 
concentrated solution of 
sulphuric acid 
 
 
No Red violet colour was 
obtained 
 
 
Absence of terpenoids 
Test for Steroids 
1. Libermann- Buchard 
Test: 
To extract add chloroform 
solution a few drops of 
acetic anhydride and 1ml of 
con. H2SO4 were added 
through the side of the test 
tube and set aside for a 
while. 
 
 
Brown ring was formed at 
the junction. 
 
 
Presence of steroids 
2. Salkowski Test: 
To the extract add 
chloroform solution few 
drops of con. H2SO4 was 
added shaken and allowed 
to stand. 
 
 
Greenish fluorescence was 
formed. 
 
 
Presence of steroids 
3. Libermann’s Reaction: 
Mix 3ml of extract with 
3ml of acetic anhydride, 
heat and cool. Add few 
drops of Con. H2SO4. 
 
 
Blue colour was formed 
 
 
Presence of steroids 
 
6. 8. Preparation of Transdermal Patch [40] 
Six batches of Aqueous Extract of leaves of Azadirachta indica A. Juss. transdermal 
patches were prepared using drug with two different polymer in three different ratio 
(1:4,1:6 &1:8). Weighed quantity of polymer was dissolved in calculated quantity of water 
and heated on a water bath. Calculated amount of extract was added to the above mixture 
and stirred well until a homogenous mixture was formed. Then calculated amount of 
permeation enhancer and glycerin were added. In all the six batches the quantity of extract 
was same. 
The resultant mixture was poured into a Petridish and air dried at room temperature 
for 24h.The patches were then peeled off from the Petridish with the help of a knife and 
kept in desiccator. 
                                               Table No.4:   Formula for TDDS 
 
Ingredients 
Formulation Code 
TP1 TP2 TP3 TS4 TS5 TS6 
AE (mg) 40 40 40 40 40 40 
Pectin (mg) 160 240 320 - -  
S.Alginate (mg) - - - 160 240 320 
DMSO (ml) 0.3 0.3 0.3 0.3 0.3 0.3 
Glycerin (ml) 0.3 0.3 0.3 0.3 0.3 0.3 
Water q.s q.s q.s q.s q.s q.s 
 
 
 
 
 
 Calculation 
Diameter of glass plate  = X cm                   
Radius of glass plate   = Y cm                  
Area of glass plate             =   r2(π=3.14)      
               = 3.14 × (y)    
                                                = Z cm2              
  Z/X= Area/diameter            = capacity (ml) 
 
6.9. Preparation of Calibration curve of Azadirachta indica A. Juss. Extract  
Accurately weighed quantity (100mg) of AE was transferred into a 100ml 
volumetric flask and dissolved in small amount of distilled water  (D.W) and made up to 
the volume to make the standard stock solution of 1 mg/ml. 
From the stock, 1ml was taken in 10ml volumetric flask and made up the volume 
with the buffer; from this solution 0.5ml to 3ml solution was transferred to 10ml 
volumetric flask and made up to required volume with more D.W and the resulting 
concentration ranges from 5 to 50 µg/ml. The absorbance of these solutions was 
determined at 382nm using UV spectrophotometer. The calibration curve was constructed 
between the absorbance and concentration.  
6.10. Preparation of phosphate buffer pH 7.4 
Phosphate buffer pH 7.4 was prepared as per the method described in I.P 1996 
using disodium hydrogen phosphate and sodium hydroxide. The pH was adjusted to 7.4 
prior to quantitative estimation. 
6.11. Physico chemical evaluation of Azadirachta indica A.Juss. Transdermal    
Patch [41,42] 
 Formulated patches were subjected to the preliminary evaluation tests. Patches 
with any imperfections, entrapped air, or differing in thickness, weight (or) content 
uniformity were excluded from further studies.  
1.  Uniformity of weight  
This was done by weighing five different patches of individual batch taking the 
uniform size at random and calculating the average weight of three. The tests were 
performed on patch which was dried at 60˚C for 4 h prior to testing.  
 
 
 2.  Thickness of the Patch 
 The thickness of the patch was assessed by using digital vernier caliper at different 
points of the patch. From each formulation three randomly selected patches were used. 
The average value for thickness of a single patch was determined. 
3.  Drug content determination  
The patches were taken and added to a beaker containing 100 ml of D.W. The    
medium was stirred magnetic bead for 5 h. The solution was later filtered and analyzed for 
drug content with proper dilution at 382 nm spectrophotometrically.  
4. Folding Endurance  
This was determined by repeatedly folding one patch at the same place till it broke. 
The number of times the patch could be folded at the same place without breaking gave 
the value of folding endurance. 
5. Percentage Moisture uptake 
The patch were weighed accurately and placed in desiccators containing 
aluminium chloride. After 24 h, the patch were taken out and weighed. The percentage 
moisture uptake was calculated as the difference between final and initial weight. With 
respect to initial weight. It is calculated by using following formula.  
         
                                                                   Final weight – Initial weight  
              Percentage moisture content =                             X 100 
               Initial weight  
 
6. Percentage Moisture content  
The patch were weighed and kept in desiccators containing calcium chloride. After 
24h the patch were taken out and weighed. The percentage moisture content was 
calculated using the following formula.                                                                                                          
                        Initial weight –Final weight  
                  Percentage moisture content =                                                         X 100 
                    Initial weight 
7. Determination of surface pH  
The patches were allowed to swell by keeping them in contact with 1 ml of 
distilled water for 2 h at room temperature and pH was noted down by bringing the 
electrode in contact with the surface of the patch, allowing it to equilibrate for 1 min.  
 
 
 8. Percent Elongation  
When stress is applied, a patch sample stretches and this is referred to as strain. 
Strain is basically the deformation of patch divided by original dimension of the sample. 
Generally elongation of patch increases as the plasticizer content increases. It is calculated 
by using following formula.  
                           Increase in length of patch 
                 Percentage elongation =                                                  X 100 
                Initial length of patch 
9. Tensile strength  
Tensile strength is the maximum stress applied to a point at which the patch 
specimen breaks. It is calculated by the applied load at rupture divided by the cross-
sectional area of the strip as given in the equation below 
                                        Load at failure 
                     Percentage elongation =                                                    X 100  
                             Patch thickness x Patch width 
The results of Physico chemical parameters are shown in  Table:14 
 
Cellophane Membrane Treatment 
Cellophane membrane was boiled in the D.W for 1 h and washed with fresh D.W 
for three times and kept in ethanol for 24 h. It was washed with D.W and treated with 
0.3% sodium sulphite and soaked in distilled water for 2 min at 60°C followed by 
acidified with 0.2% sulphuric acid. Finally the membrane was dipped in boric buffer (pH 
9) till it is used for permeation study. 
Drug Permeation Studies [43] 
The in vitro diffusion rate of Azadirachta indica A. Juss. transdermal patches were 
evaluated by open ended tube through using distilled water as diffusion medium up to 8 h 
studies. The cellophane membrane was tide in one end of the tube and then immersed in 
the receptor compartment containing 200ml of 7.4 buffer solution. Which was stirred at 
medium speed and maintained at 37°C±2°C. Samples were withdrawn at regular time 
intervals and the same volume was replaced by fresh diffusion medium.  The samples 
were analyzed using UV – visible spectrophotometer (Shimadzu UV1700) set at 382 nm.  
The results are shown in Table 25 and Fig No 33  
 
 
6.12. Experimental conditions of ex vivo transdermal permeation study of  P2 
formulation44 
Ex vivo Transdermal permeation studies carried out using Goat abdomen skin  
 The receptor compartment consisted of 400ml of Phosphate buffer (pH 7.4) in 
500 ml beaker  
 Temperature was maintained at 37 ± 0.5°C and stirred at 900 rpm  
 The Azadiractha indica A Juss. Transdermal patch was placed in Goat abdomen 
skin and tied to the one end of open-ended glass cylinder that was then dipped 
into freshly prepared phosphate buffer on magnetic stirrer  
 Samples were taken from receptor medium at 0, 30, 60, 90, 120, 150, 180, 210, 
240 and 270, 300, 330,360 , 390, 420, 660, 720 min  
 Periodically 5ml of sample was withdrawn and same volume of medium was 
replaced with fresh buffer  
 All the Samples were assayed spectrophotometrically at 382 nm using PB 7.4 
pH as blank  
The result shown in Table:31 and Fig No52 
 
6.13. Diffusion Kinetics [45] 
Data obtained from in-vitro diffusion studies were fitted to various kinetic 
equations. The kinetic models used are zero order equations (Q=k0t), First order equation 
{ln (100 – Q) =ln Q – klt}, Higuchi equation (Q=kt1/2), Hixson and crowell model Qt1/3 
Vs t and Qt2/3 Vs – Modified root cube equation. Further, to find out the mechanism of 
drug diffusion, first 60% drug diffusion was fitted in Korsmeyer and Peppas equation 
(Q=kptn). Where, Q is the percent of the drug diffusion at time t and k0 and kt are the 
coefficients of the equations and ‘n’ are the diffusion exponent. The ‘n’ value is used to 
characterize different diffusion mechanism. 
The order of drug diffusion can be assessed by graphical treatment of drug 
diffusion data.  
A plot of cumulative % drug diffusion versus time would be linear if the drug 
diffusion follows zero order (i.e. Concentration independent diffusion).  
 
A plot of log of % remaining drug versus time would be linear, if the drug 
diffusion follows first order (i.e. Concentration dependent diffusion)  
 
 The linear equation for zero order drug diffusion plot is:  
Ct = C0 – Kt 
Where,  
Ct = concentration remaining at time t,  
Co = original concentration,  
t = time,  
K = diffusion rate  
The linear equation for first order diffusion plot is  
                      logC0Kt  
              Log C =         ------------  
                         2.303  
A matrix device as the name implies, consists of drug dispersed homogeneously 
throughout a polymer matrix 
In this model, drug in the outside layer exposed to the bathing solution is dissolved 
first and then diffuses out of the matrix. This process continues with the interface between 
the bathing solution and the solid drug moving towards the interior. Obviously, for this 
system to be diffusion controlled, the rate of dissolution of drug particles within the matrix 
must be much faster than the diffusion rate of dissolved drug leaving the matrix. 
Hydrophilic matrix tablets contain a water swellable polymer. On 
[1 – Mt / M] 1/3 = 1-kt  
Where,  
Mt = mass of drug diffusion at time t,  
M = mass diffusion at the infinite time,  
K = rate of erosion,  
t = time  
Thus a plot of [1 – Mt / M] 1/3 versus the time will be linear. If the diffusion of 
drug from the matrix is erosion controlled.  
In order to ascertain whether the drug diffusion occurs by diffusion or erosion, the 
drug diffusion data was subjected to following modes of data treatments.  
1) Amount of drug diffusion versus square root of time (Higuchi Plot).  
2) [1 – Mt / M] 1/3 versus time.  
 
 
 
6.14.Stability studies [46,47] 
a) Stability 
Stability is official defined as the time lapse during which the drug product retains 
the same property and characteristics that it possessed at the time of manufacture. This 
process being  early development phases. 
Instability in modern formulation is often undetectable only after considerable 
storage period under normal conditions. To assess the stability of a formulated product it is 
usual to expose it to high stress conditions to enhance deterioration and therefore the time 
required for testing is reduced. Common high stresses are temperature and humidity. This 
will eliminate unsatisfactory formulation.  
b) Strategy of stability testing  
 The study of drug decomposition kinetics  
 The development of stable dosage form  
 Establishment of expiry date for commercially available drug product is some of 
the needs of stability testing  
 Data from which study should be provided on at least 3 primary batches of the 
drug product  
 The batches should be manufactured to a minimum of pilot scale  
 Important point of view of the safety of the patient, patient relieves a uniform dose 
of drug throughout the shelf life of the product 
Table No.5: Stability condition chart 
Intended 
Storage 
Condition 
StabilityTest 
Method 
ICH Test 
Temperature and 
Humidity (period in 
months) 
WHO Test 
Temperature and 
Humidity(period in 
Months) 
Room 
Temperature 
Long term 25±20C/60±5%RH 25±20C/60±5%RH or 
30±20C/65±5%RH 
30±20C/75±5%RH 
Intermediate 30±20C/65±5%RH 30±20C/65±5%RH 
Accelerated 40±20C/75±5%RH 40±20C/75±5%RH 
Refrigerated Long term 
Accelerated 
50C/ambient 
25±20C/60±5%RH 
5±30C 
25±20C/60±5%RH  or 
30±20C/65±5%RH 
Freezer Long term -200C/ambient -200C±50C 
 
 
6.15. Screening of Antimicrobial activity of Azadirachta indica A.Juss. [48,49,50] 
6.15.1. Anti-Bacterial Activity 
Principle 
  Discs impregnated with known concentration of antibiotics discs are placed on 
agar plate that has been inoculated (or) seeded uniformly over the entire plate with a 
culture of the bacterium to be tested. The plate is incubated for 18-24 hrs at 37oC. During 
this period, the antibacterial agent diffuses through the agar and may prevent the growth of 
organism. Effectiveness of susceptibility is proportional to the diameter of inhibition of 
zone around the disc. Organisms which grow up to the edge of the disc are resistant. 
A) Materials Required 
Peptone, Sodium Chloride, Dil. Sodium Hydroxide, Dil. Sulphuric acid, Agar, 
Distilled water, pH paper, Conical flask, Culture tubes, Glass rod, Non-absorbant 
cotton, Autoclave- Micropipette, Petri dishes and Incubator. 
 B) Experimental condition 
Organisms used : Bacillus subtilis, Staphylococcus aureus,   
                           Pseudomonas aeruginosa 
Media used  : Nutrient Agar. 
Test used  : AE patch 
Standard  : Ciprofloxacin, Nystatin 
C) Preparation of Nutrient Agar 
  8.2 gm of agar powder was dissolved in 250 ml of water. The medium was 
steamed in boiler to precipitate any heat coagulable material. Then the medium was 
filtered. The filtrate was distributed in 5ml quantity in to culture tubes. The tubes were 
plugged with non-absorbent cotton. The medium in the tubes were sterilized by autoclave 
not less than 15 minutes at 15 pounds per sq. inch at 121oC. 
D) Preparation of Paper Disc 
  By using standard punching machine what man filter paper was cut and standard 
paper of 6.0 mm diameter was prepared. The paper discs were sterilized in a hot air oven 
at 160oC for 1hour. The paper discs were then impregnated with the test solution. 
 
 
 
 
 
 6.15.2. Anti-Fungal Activity 
Principle 
  Discs impregnated with known concentration of antibiotics discs are placed on 
Modified Sabouraud’s Glucose agar plate that has been inoculated (or) seeded uniformly 
over the entire plate with a culture of the fungi to be tested. The plate is incubated for 3 
days 18-24 hrs at 37oC. During this period, the antifungal agent diffuses through the agar 
and may prevent the growth of organism. Effectiveness of susceptibility is proportional to 
the diameter of inhibition of zone around the disc. Organisms which grow up to the edge 
of the disc are resistant. 
A) Materials Required 
  Glucose, Peptone, yeast extract, Glycerin monostearate, Olive oil, Tween 80, 
Chloramphenicol,  Agar, Distilled water, pH paper, Conical flask, Culture tubes, Glass 
rod, Non-absorbant cotton, Autoclave, Micropipette Petri dishes and Incubator.  
B) Experimental condition 
Organisms used : Candida albicans,   Aspergillus niger. 
Media used  : Modified Sabouraud’s Glucose Agar medium 
Test used  : AE patch, 
Standard   : Ciprofloxacin, Nystatin 
 
  
 
 
 
 
 
 
 
 7. RESULTS AND DISCUSSIONS 
7.1. Absorption maxima (Ȝ max)  of Aqueous Extract of Azadirachta  indica A. Juss 
 
          Fig No.20: Absorption maxima (Ȝ max) of Aqueous Extract of Azadiractha  
indica  A Juss. 
The sharp peak observed at 382 nm, further measurements were taken at 382nm. 
7.1.1. Standard Curve values of Aqueous  Extract of Azadirachta indica A. Juss 
          Table No.6: Standard values of Aqueous Extract of Azadirachta indica A. Juss 
 
         
 
Concentration 
(g/ml) 
Absorbance      
at 382 nm 
 Average SD 
0 0.000 0.000 
              10 
 
0.091 0.001 
20 
 
0.182 0.001 
30 
 
0.273 0.001 
40 
 
0.363 0.001 
50 
 
0.432 0.001 
60 0.512 
Mean ± S.D: n = 3 
 
  
              Fig No.21: Standard Curve of Aqueous  Extract of Azadirachta indica A.Juss  
  7.2. Physical appearance 
Colour  :  Green 
Taste  :  Bitter taste 
Solubility        :           Freely soluble in Distilled Water 
7.3. Phytochemical Studies 
Table No.7: Phytochemical constituents 
 
 
  
(+) Presence of constituents       (-) Absence of constituents 
The phytochemical studies revealed that the presence of alkaloids, saponins, 
tannins, phenolic compounds, flavonoids and sterol. 
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 7.4. Hygroscopic Nature 
Table No. 8. Hygroscopic Nature determination 
        At Room Temperature 75%RH at 400C 
Sample No-1 Sample No-1 
Weight gain observed (0.41±2.1) Weight gain observed (0.38±0.6) 
The results, it is observed that the prepared Transdermal patch is hygroscopic in 
nature. 
7.5. Compatibility study  
FTIR studies 
 
         Fig No. 22: FTIR Spectrum of Aqueous Extract of  Azadirachta indica A. Juss 
 
 
  Table No. 9. FTIR Interpretation of Aqueous Extract of Azadirachta indica A. Juss 
Wave number (cm-1) Functional Group 
              3391.615               C=O stretching  
2931.66  C-H Stretching  
1637.95  C-C Stretching  
1414.22  OH Bending  
921.39  C-O Stretching  
 763.74, 653.03  C-H Rocking  
 
 
PCP-Neem Extract-
Name Description
4000 4003500 3000 2500 2000 1500 1000 500
100
0
10
20
30
40
50
60
70
80
90
cm-1
%
T
3391.44cm-1
1027.74cm-1
1568.01cm-1
1414.22cm-1
1079.04cm-1
1152.19cm-1
2931.02cm-1
1637.95cm-1
578.76cm-1
618.05cm-1
653.90cm-1
532.93cm-1
1301.67cm-1
708.63cm-1
1242.69cm-1
7 6 2 . 4 5 c m - 1
1204.10cm-1
930.35cm-1
844.05cm-1
  
 
 
Fig No. 23: FTIR spectrum of Pectin 
 
 
Table No.10: FTIR Interpretation of Pectin 
 
 
  
              
 
 
  
 
 
 
 
 
PCP-Pectin-
Name Description
4000 4003500 3000 2500 2000 1500 1000 500
100
0
10
20
30
40
50
60
70
80
90
cm-1
%
T
3409.65cm-1
1566.09cm-1
1415.29cm-1
1030.96cm-1
1635.11cm-1
1077.07cm-1
2934.66cm-1
1103.46cm-1
650.03cm-1
535.68cm-1
770.74cm-1
2166.49cm-1
921.39cm-1
Wave number (cm-1) Functional groups 
3409.65 C=O stretching 
2934.66 C-C stretching 
1635.11 C-C stretching 
1415.29 OH bending 
921.39 C-O Stretching 
770.76 CH Rocking 
  
                                Fig No. 24: FTIR spectrum of Pectin formulation 
 
         
Table No.11: FTIR Interpretation of Pectin formulation 
 
  
 
  
 
 
 
 
 
 
PCP-Pectin film-
Name Description
4000 4003500 3000 2500 2000 1500 1000 500
100
0
10
20
30
40
50
60
70
80
90
cm-1
%
T
3314.33cm-1
3220.18cm-1
3287.04cm-1
3462.17cm-1
3439.45cm-1
3340.56cm-1
3239.77cm-1
3263.97cm-1
3513.91cm -1
3172.91cm-1
3419.27cm-1
3395.99cm-1
1126.67cm-1
2934.70cm-1
1016.49cm-1
1065.60cm-1
1094.92cm-1
1418.86cm-1
1332.02cm-1
1361.04cm-1
634.07cm-11231.66cm-1
1 7 4 0 . 8 6 c m - 1
957.90cm-1
537.35cm-11632.10cm-1
759.39cm-1
9 2 3 . 4 0 c m - 1
836.11cm-1
Wave number (cm-1) Functional groups 
3462.17 C=O stretching 
1740.66 C-C stretching 
1632.11 C-C stretching 
1126 OH bending 
923.100 C-O Stretching 
759.39                 CH Rocking 
 
  
           
       
 
 
 
 
 
                                    
 
 
 
Fig.No. 25: FTIR Spectrum of Sodium alginate 
 
 
 
 
Table No. 12: FTIR Interpretation of sodium alginate 
  
  
     
                                              
 
  
 
 
 
 
  Wave number (cm-1) Functional groups 
1 3428.58 C-H stretching 
2 2925.88 C-H stretching 
3 1620.09,1416.26 C-C multiple bond stretching 
4 1416.26 O-H stretching 
  
 
 
 
            
 
 
  
 
 
Fig No. 26:  FTIR Spectrum of Sodium alginate formulation 
 
 
Table No.13: FTIR Interpretation of Sodium alginate formulation 
 
 
 
 
 
 
The FTIR graphs of drug, excipients and formulations results showed that there is 
no extra peak (or) broadening of peaks were observed and thus it indicates that there is no 
incompatibility between drug and excipients. 
Wave number (Cm-1) Functional groups 
3355.17 O-H stretching 
1414.53 O-H bending 
1045.91 C-O stretching 
1115.29 C-O stretching 
1045.09 C-O stretching 
810.36 C-H ( Out plane bending) 
694.63 C-H ( Out plane bending) 
ACIC
St.Joseph's College ( Autonomous)
Trichy-2
Spectrum Name: PCP-P2.sp 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 600 400.0
0.0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100.0
cm-1
%T 
3355.17
3177.98
2951.48
2272.84
2057.68 1893.03
1644.88
1512.27
1414.53
1303.74
1241.51
1169.52
1045.09
810.36
694.63
534.99
  
7.6. Physico chemical evaluation of Aqueous Extract of Azadirachta indica A. Juss Transdermal patch 
 
Table No.14: Physico chemical evaluation of Aqueous Extract of Azadirachta indica A. Juss Transdermal patches 
Formulation code Uniformity 
of weight 
(g) 
Thickness 
(mm) 
Drug 
content 
(%) 
Folding 
Endurance 
e(no’s) 
Moisture
Uptake 
(%) 
Moisture 
Content 
(%) 
Surface 
pH 
Percent 
Elongation 
(% mm) 
Tensile 
Strength 
(Kg/mm2) 
Transdermal 
Patch of 
Pectin (P) 
P1 0.38±0.14 0.43±0.73 85.23±0.92 235±0.76 2.14±0.08 2.866±0.07 7.1±0.10 85±0.32 5.300±0.55 
P2 0.46±0.85 0.49±0.23 85.69±0.56 249±0.23 2.85±1.03 3.422±0.22 7.3±0.72 91±1.11 6.361±0.87 
P3 0.49±0.10 0.50±1.13 88.98±0.16 254±0.36 3.79±1.03 3.940±0.36 7.2±0.72 86±1.08 6.7031±0.87 
Transdermal 
Patch of 
Sodium 
alginate 
(S) 
S4 0.39±0.43 0.36±0.33 82.03±0.22 241±0.72 2.75±0.65 1.736±0.46 7.0±0.33 82±0.23 5.513±0.86 
S5 0.41±0.65 0.45±0.76 83.35±0.94 265±0.44 1.97±0.44 1.657±0.03 7.1±0.12 87±0.92 6.253±0.62 
S6 0.48±0.50 0.47±0.16 80.13±0.40 247±0.42 2.79±0.35 2.457±0.03 7.2±0.12  89±0.86 6.432±0.74 
 
Mean ± S.D: n = 3 
 
           The six (P1, P2,P3,S4 S5, S6) batches of extract loaded patches with different ratios of two different polymers were 
subjected  to various physicochemical evaluations. 
           Based on thickness, uniformity of weight, folding endurance, percentage moisture uptake moisture content and tensile 
strength, the formulations P2 and S5 were selected for further studies. 
     7.7. Optimized formula of Azadirachta  indica A Juss. Transdermal patch 
     Table No.15: Optimized formula of Azadirachta  indica A Juss. Transdermal patch 
 
7.8.Pictures of Prepared Patches 
 
 
 
  
 
                                           Fig No. 27: Transdermal Patch of P1 
 
 
 
 
 
                                            Fig No. 28: Transdermal Patch of P2 
 
 
 
 
 
                                         Fig No. 29: Transdermal Patch of P3 
S.NO. Ingredients P 
(Pectin) 
S 
(Sodium alginate) 
1.  Extract (mg) Azadirachta indica   40 40 
2.  Polymer (mg) 240 240 
3.  DMSO/SLS(ml) 0.3 0.3 
4.  Glycerin (ml) 0.3 0.3 
5.  Water (ml) q.s q.s 
  
                                     
 
   
 
 
 
Fig No.30: Transdermal Patch of S4 
 
 
 
 
 
 
 
                              
                                     Fig No. 31: Transdermal Patch of S5 
 
 
 
   
 
 
                                         
 
                                          Fig No. 32: Transdermal Patch of S6 
 
 
 
 
 
 
 
 7.9. Physicochemical Evaluation of Selected formulations  
Table No. 16: Uniformity of weight 
 
 
 
                    
Mean ± S.D: n= 3 
Table No. 17: Thickness of the patch 
S. No. Formulation code Thickness (mm) 
 
              1. Pectin (P2) 0.49±0.23 
  2. Sodium alginate (S5) 
 
0.45±0.76 
Mean± S.D:n=3 
 
Table No. 18: Determination of Drug content 
S. No. 
 
Formulation code % Drug content 
1.  Pectin (P2) 85.69±0.56 
2.  Sodium alginate (S5) 
 
83.35±0.94 
                                     Mean ± S.D: n=3 
 
Table No. 19: Folding Endurance 
S. No. 
 
Formulation code Folding 
Endurance 
1. 
 
Pectin (P2) 249±0.23 
2. 
 
Sodium alginate (S5) 
 
245±0.44 
Mean ± S.D: n =3 
Table No. 20: Percentage Moisture Uptake 
S. No. 
 
Formulation code 
 
% Moisture 
uptake 
1.  Pectin (P2) 2.85±1.03 
2.  Sodium alginate (S5) 
 
1.97±0.44 
 
 
S. No. 
 
Formulation code Weight(g) 
1.  Pectin (P2) 0.46±0.85 
2.  Sodium alginate (S5) 
 
0.41±0.65 
 Table No. 21: Percentage Moisture Content 
S. No. 
 
Formulation code % Moisture 
content 
1.  Pectin (P2) 3.422±0.22 
2.  Sodium alginate (S5) 
 
1.657±0.03 
Mean ± S.D: n=3 
 
 
                                                      Table No. 22: Surface pH  
S. No. 
 
Formulation code Surface pH of 
patches 
1.  Pectin(P2)  
 
7.3±0.72 
2.   Sodium alginate(S5) 7.1±0.12 
                                   Mean ± S.D: n=3 
 
 
                                                     Table No. 23: Percent Elongation 
S. No. 
 
Formulation code % Elongation 
(%mm) 
1.  Pectin(P2)  91±1.11 
2.  Sodium alginate(S5) 
 
87±0.92 
Mean ± S.D: n=3 
 
Table No.24: Tensile Strength 
S. No. 
 
Formulation code Tensile strength 
(kg/mm2) 
1.  Pectin(P2) 6.361±0.65 
2.  Sodium alginate(S5) 6.253±0.25 
                   Mean ± S.D: n=3 
 
 
 
 
 
 7.10. In vitro drug difuusion study 
Table No.25: In vitro drug diffusion study  
Time in 
(min) 
 
 
% drug diffusion 
Pectin (P) Sodium Alginate(S) 
P1 P2 P3 S4 S5 S6 
0 0 0 0 0 0 0 
30 6.78 5.2 2.98 7.15 4.86 3.46 
60 10.30 8.6 4.78 12.36 9.5 5.72 
90 13.65 11.21 5.64 16.19 11.98 9.34 
120 17.89 15.96 7.15 20.72 16.28 12.20 
150 23.10 18.54 9.45 24.37 20.41 17.40 
180 29.54 22.34 14.82 30.97 25.01 22.19 
210 33.68 27.45 19.38 34.65 32.21 25.30 
240 39.70 31.23 25.48 38.98 36.43 29.68 
270 45.58 38.42 30.98 43.12 42.11 33.76 
300 48.77 43.58 38.73 48.94 46.36 36.15 
330 53.22 49.86 42.54 54.30 52.21 42.56 
360 57.10 55.25 45.24 59.61 55.34 47.26 
390 62.41 60.46 49.64 65.73 59.43 53.90 
420 67.38 65.46 53.28 68.60 64.22 58.76 
450 72.34 69.46 59.74 70.12 68.18 63.12 
480 77.10 73.04 64.10 74.62 71.46 67.92 
  
Fig No.33:In vitro drug diffusion study 
Table No. 26: In vitro drug diffusion profile of P2 
S. No. Time (min) % Drug diffusion of 
P2 
1.  0 0 
2.  30 5.2± 0.23 
3.  60 8.6± 0.45 
4.  90 11.21± 0.44 
5.  120 15.96± 0.76 
6.  150 18.54± 1.78 
7.  180 22.34± 0.59 
8.  210 27.45± 1.23 
9.  240 31.23 ± 0.61 
10.  270 38.42±1.24 
11.  300 43.58± 1.90 
12.  330 49.86±1.54 
13.  360 55.25± 0.23 
14.  390 60.46± 1.34 
15.  420 65.46± 0.91 
16.  450 69.46± 0.72 
17.  480 73.04± 0.61 
Mean±S.D:n=3 
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Fig No.34: In vitro drug diffusion  profile of P2 
 
Table No. 27 : In vitro drug diffusion  profile of S5 
S.No 
 
Time (min) % Drug diffusion of S5 
1 0 0 
2 30 4.86± 0.23 
3 60 9.95± 0.45 
4 90 11.98± 0.44 
5 120 16.28± 0.76 
6 150 20.41± 1.78 
7 180 25.01± 0.59 
8 210 32.21± 1.23 
9 240 31.23 ± 0.61 
10 270 42.11±1.24 
11 300 46.36± 1.90 
12 330 52.21±1.54 
13 360 55.34± 0.23 
14 390 59.43± 1.34 
15 420 64.22± 0.91 
16 450 68.18± 0.72 
17 480 71.46± 0.61 
Mean S.D:n=3 
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Fig No.35: In vitro drug diffusion profile of  S5 
 
Table No.28 : Comparative in vitro drug diffusion profile 
S.No. 
 
Time (min) 
% of  drug 
diffusion 
P2 
% of drug  
diffusion 
S5 
1 0 0 0 
2 30 5.2± 0.23 4.86± 0.23 
3 60 8.6± 0.45 9.95± 0.45 
4 90 11.21± 0.44 11.98± 0.44 
5 120 15.96± 0.76 16.28± 0.76 
6 150 18.54± 1.78 20.41± 1.78 
7 180 22.34± 0.59 25.01± 0.59 
8 210 27.45± 1.23 32.21± 1.23 
9 240 31.23 ± 0.61 31.23 ± 0.61 
10 270 38.42±1.24 42.11±1.24 
11 300 43.58± 1.90 46.36± 1.90 
12 330 49.86±1.54 52.21±1.54 
13 360 55.25± 0.23 55.34± 0.23 
14 390 60.46± 1.34 59.43± 1.34 
15 420 65.46± 0.91 64.22± 0.91 
16 450 69.46± 0.72 68.18± 0.72 
17 480 73.04± 0.61 71.46± 0.61 
Mean S.D:n=3 
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Fig No.36: Comparative in vitro drug diffusion profile  
The selected 2 batches of formulations Pectin (P2), Sodium alginate (S5) were subjected 
comparative in vitro permeation studies. Formulation P2 showed sustained diffusion in a 
controlled manner upto 8 hrs.  
 
7.11. Release Kinetics  
            Table No: 29. In vitro Release kinetics values 
 
Formulation 
code 
Correlation coefficient(r2)      ‘n’-
Diffusion 
Exponent 
Zero 
order 
First 
order 
Higuchi Korsmeyer 
peppas 
P2 0.997 0.976 0.883 0.882 0.865 
S5 0.991 0.945 0.997 0.853 0.853 
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 Fig No.37: Zero order kinetic plot of P2  
 
                                      Fig No.38: First order kinetics plot of  P2 
 
                                                       Fig No.39: Higuchi plot   P2 
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Fig No.40: Korsmeyer peppas plot of P2 
  
Fig No.41: Zero order plot of  S5 
 
Fig No.42: First order plot of S5 
y = 0.579x + 0.470
r² = 0.882
0
0.5
1
1.5
2
2.5
0 1 2 3
Lo
g 
 
cu
m
 
%
 
dr
u
g 
re
le
a
se
Log time
Korsmeyer Peppas plot
P2
Linear (P2)
y = 0.31x + 2.781
r² = 0.991
0
50
100
150
0 200 400 600C
um
 
%
 
dr
u
g 
re
le
a
se
 
Times in min
Zero Order plot
S5
Linear (S5)
y = -0.001x + 2.046
r² = 0.945
0
0.5
1
1.5
2
2.5
0 200 400 600
lo
g 
%
 
dr
u
g 
re
le
a
se
Time   in min
First odrer plot 
S5
Linear (S5)
   
 
 Fig No. 43: Higuchi plot of S5   
 
Fig No.44: Korsmeyer peppas plot of S5 
Release kinetics study revealed that both (P2 & S5) selected patches follows zero 
order and non fickian diffusion model. So they were subjected to antimicriobial screening. 
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 7.12. Screening of Antimicrobial activity of  Azadirachta   indica A. juss 
  The anti - microbial activity for the given sample was carried out by disc diffusion 
technique (Indian Pharmacopoeia 1996, vol II A-105). The test micro organism of 
Staphylococcus aureus, Bacillus subtilis, Klebsiella pneumonia and Proteus vulgaries and  
fungus Aspergilus niger, Candida albicans were obtained from National Chemical 
Laboratory (NCL) Pune and maintained by periodical sub culturing on nutrient agar and 
sabouraud dextrose agar medium for bacteria and fungi respectively. The effect produced by 
the sample was compared with the effect produced by the positive control (reference standard 
Ciprofloxacin 5µg/ disc for bacteria; Nystatin100µg/ disc for fungi).  
For Fungi 
  After 72h the plates were observed. The zone of inhibition was calculated by 
measuring the minimum dimension of the zone of no fungal growth around the patch The 
figures are shown in 45 & 46 and the results are shown in Table  No: 31. 
For Bacteria  
After 24h the plates were observed. The zone of inhibition was calculated by 
measuring the minimum dimension of the zone of no bacterial growth around the patch. The 
Figures are shown in 47&48 and 49&50 results are in Table No: 30. 
 
FUNGI 
            
Fig No. 45: Aspergillus niger                    FigNo.46: Candida albicans 
 
                               
                                               GRAM  POSITIVE BACTERIA 
           
Fig No.47:Bacillus subtilis                           Fig No.48:Staphylococcus aureus 
                                 
 
                             GRAM  NEGATIVE BACTERIA    
          
Fig No. 49: Klebsiella pneumonia                      Fig No. 50: Proteus vulgaries 
 
 
 
 
 
 
 
 
 
 
  
 
Table No: 30. Screening of Antimicrobial activity 
S.No. Name of the 
microorganism 
A B C D E 
1.  Aspergilus Bniger    
(NCIM 105) 15 - 14 - 35 
2.  Candida  albicans     
(NCIM 3102) 20 - 15 
- 32 
3.  Bacillus  subtilis 
(NCIM 2063) 17 - 17 
- 40 
4.  Staphylococcus  
aureus 
(NCIM 2079) 
15 - 15 
- 
 
35 
5.  Klebsiella  
pneumonia 
(NCIM 2098) 
18 - 16 
 
- 
30 
6.  Proteus   vulgaries 
(NCIM 2027) 21 - 15 
- 
30 
  
 
A: Pectin (P2); B:  pectin without drug patch ; C: Sodium alginate (S5)  ; D: sodium alginate 
without drug & Standard :(Ciprofloxacin 5µg/ disc for bacteria; Nystatin 100 µg/ disc for 
fungi) 
 
When compared to S5, P2 showed greater inhibition against  Candida  albicans, Klebsiella  
pneumonia and Proteus   vulgaries. So P2 has been selected for ex vivo and stability studies. 
 
 
 
 
 
 
 
 
7.13. Ex vivo study  
  
 
Fig No. 51 :Goat abdomen skin tied on open ended cylinder 
 
Table No: 31. Ex vivo Transdermal Permeation of  P2 
 
 
 
 
 
 
 
 
 
 
 
S. No. Time in min % Drug diffusion 
1 0 0 
2 30 0.30±0.15 
3 60 0.43±0.53 
4 90 1.35 ±0.71 
5 120 2.23±0.62 
6 150 3.12±0.45 
7 180 6.45±0.47 
8 210 11.28±0.16 
9 240 20.45±0.32 
10 270 27.70±0.06 
11 300 33.10±0.83 
12 330 37.56±0.71 
13 360 40.24±0.71 
14 390 45.26±0.63 
15 420 53.43±0.68 
16 450 58.34±0.24 
17 480 61.01±0.63 
  
Fig No. 52: Ex vivo drug permeation of P2  
 
7.14. Ex vivo Diffusion Kinetics  
 
Table No: 32. Ex vivo release kinetic values 
 
Formulation 
code 
Correlation coefficient(r2)      ‘n’-
Diffusion 
Exponent 
Zero 
order 
First 
order 
Higuchi Korsmeyer 
peppas 
Ex-vivo (P2) 0.907 0.845 0.720 0.945 0.915 
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Fig No.53: Zero order plot of ex vivo drug diffusion of P2 
 
 
  
Fig No.54: First order plot of ex vivo drug diffusion of P2 
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Fig No.55: Higuchi plot of ex-vivo drug release of P2 
 
 
 
Fig No.56: Korsmeyer peppas plot of  ex vivo diffusion of P2 
 
                  Ex vivo drug diffusion kinetics of P2 shows that it follows zero order and non 
fickian diffusion model 
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 7.15. Stability study of Aqueous Extract of Azadirachta indica A Juss. Transdermal 
Patch 
Table No: 33. Stability study of P2 
 
 
 
 The stability studies of formulation of  aqueous extract of Azadirachta indica A Juss. 
transdermal patch was carried out for 3 months as per the procedure described in the table 
.No:5. During this period, the formulations were stable and showed no significant changes in 
visual appearance, colour, texture and drug content. 
 
 
Parameter Room temperature 40±20C& RH 
70±5% 
Visual Appearance Brown colour Brown colour 
Initial No change No change 
At the end of 1st month No change No change 
At the end of 2nd month No change No change 
At the end of 3rd month No change No change 
Colour  Brown  Brown 
Initial No change No change 
At the end of 1st month No change No change 
At the end of 2nd month No change No change 
At the end of 3rd month No change No change 
Texture Smooth Smooth 
Initial No change No change 
At the end of 1st month No change No change 
At the end of 2nd month No change No change 
At the end of 3rd month No change No change 
Drug content No change No change 
Initial 85.69% 85..69% 
At the end of 1st month 85.22% 85.14% 
At the end of 2nd month 84.95% 84.81% 
sAt the end of 3rd month 84.21% 84.06% 
8.1. SUMMARY AND CONCLUSION 
  
 Six batches of (P1, P2, P3, S4, S5 & S6) Aqueous extract of Azadirachta indica 
transdermal patches were prepared by solvent casting technique. 
 The various formulation parameters, Drug-Polymer ratios and permeation enhancers 
were optimized to get thin, transparent, smooth, stable and high permeable transdermal patches. 
 The FTIR graphs of drug, excipients and formulations showed that there is no extra 
peak (or) broadening of peaks were observed and thus it indicates that there is no incompatibility 
between drug and excipients. 
  From the optimization, best 2 formulations P2 & S5 were selected based on physico 
chemical evaluation and in vitro drug diffusion study 
 0.3ml of glycerin was added as plasticizer to produce a flexible patch without having 
major influence on their diffusion property. If the amount exceeds, the film loses its flexibility 
and become stiff. 
 The plasticizer diffuses through the patch and softens the polymer particles. This 
softening promotes latex coalescence and patch formation. 
 All the six batches were evaluated for Percentage Moisture uptake, Percentage 
Moisture content, Thickness, Folding Endurance, Percentage Drug content, Percent Elongation, 
Tensile strength and Adhesive strength. 
 The formulations P2 & S5 showed maximum % Moisture uptake,  Moisture content, 
Thickness, folding endurance, % Drug content, Percent elongation, Tensile strength 
 No significant difference in drug content was observed between the patches among 
the six formulations. This indicates the homogenous dispensing of drug during the patch 
preparation.  
  
  
 The data obtained from in vitro diffusion profile of selected formulations were fitted 
with various kinetic equations to determine the mechanism of drug diffusion and diffusion rate as 
indicated by higher correlation coefficients (r2). The drug diffusion from P2 & S5 follows zero 
order and non-fickian diffusion. 
 These findings indicates that the drug diffusion from the P2 & S5 patch was diffusion 
controlled. 
    From the results of in vitro diffusion and physicochemical studies, P2 & S5 was 
concluded as best formulation. Then they were  subjected to screening of anti microbial activity 
   The anti microbial screening result showed that the P2 was highly inhibit the microbial 
growth around the patch. So, P2 was selected for further evaluations such as  ex vivo  and 
stability studies. 
   The ex vivo studies results showed 61.01% of drug diffusion at the end of 8 h. It 
concluded the controlled diffusion property of  through the skin   
       . The stability studies results showed that there is no significant change from its initial nature 
till the period of three months at 40˚C ±2˚C/75 5% RH. 
     The present work has achieved the objectives of formulation of transdermal patch of 
Aqueous extract of Azadirachta indica by using different polymers. The diffusion kinetics 
confirms that the formulation followed zero order, non-fickian diffusion model. 
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